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1. OVERVIEW 
Global obesity is a pandemic status, estimated to affect over 2 billion people, and has resulted in an 
enormous strain on healthcare systems worldwide. The situation is compounded by the fact that apart from 
the direct costs associated with overweight pathology, obesity presents itself with a number of 
comorbidities, including an increased risk for the development of neurodegenerative disorders. Alzheimer 
disease (AD), the main cause of senile dementia, is no exception. Spectacular failure of the pharmaceutical 
industry to come up with effective AD treatment strategies is forcing scientific community to rethink the 
underlying molecular mechanisms leading to cognitive decline. To this end, the emphasis is once again 
placed on the experimental animal models of the disease. Research described in this doctoral thesis is 
focused on the effects of a high-fat diet (HFD) in C57/Bl6 Wild-type (wild-type) and APPswe/PS1dE9 
(APP/PS1) mice, a well-established mouse model of familial AD. 
The introductory sections which follow are aimed to inform the reader of the broader scientific context to 
which current work applies. Section 2 describes how fundamental science has shaped our understanding of 
the molecular basis of AD. Key findings and the associated hypotheses are presented in chronological order. 
In my opinion, by structuring the introduction in this manner, the incremental nature of scientific discovery 
becomes more evident. This format has also allowed me to address some of the more obscure and currently 
discredited hypotheses, notably the “Aluminium hypothesis”. The history of fundamental research is 
littered with discarded and forgotten ideas, and it was important to me to highlight this frequently 
overlooked aspect of basic research. In Section 3, the pharmacological approaches to AD treatment are 
summarized. The purpose of that section is not to go into exhaustive detail concerning any particular 
compound or a molecule. Rather, an attempt is made to stress that a very large number of pharmaceuticals 
targeting diverse pathways were considered as a possible therapy and failed. It is by no means uncommon 
to see Phase III clinical trials with thousands of recruited patients failing to meet the primary outcomes due 
to lack of efficacy. The present work will not solve the problem of AD, however it does address a specific 
molecular aspect of the pathology. That is the role of metabolism in the relatively early stages of the disease.
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2. ALZHEIMER DISEASE: A BRIEF HISTORY 
Over a century has passed since Alzheimer Disease (AD) was first identified by German physician Alois 
Alzheimer. In his now famous 1907 report titled “Über eine eigenartige Erkrankung der Hirnrinde” (About 
a peculiar disease of the cerebral cortex), Dr. Alzheimer described the case of a 51-year old patient Auguste 
Deter (Alzheimer, 1907). What started off as strong feelings of jealousy towards her husband, had rapidly 
progressed towards significant memory deterioration, cognitive impairments and hallucinations. By the 
time of her death, 4 and a half years post-hospitalization, the patients’ health deteriorated completely as she 
had lost all sense of her surroundings, was incontinent and confined to bed in fetal position. The autopsy 
revealed what are now known as the classical morphological symptoms of AD: neurotic (now known to be 
composed of amyloid peptide) plaques and neurofibrillary tangles (now known to be composed of Tau 
protein) in the cerebral cortex (Fig.1 on page 17). A recent re-evaluation of the DNA material extracted 
from the histopathological slides of Auguste Deter’s brain had identified a mutation in presenilin 1 (PS1) 
gene as responsible for disease development in this first documented case of AD (Rupp, Beyreuther, 
Maurer, & Kins, 2014). This section will provide a brief historical overview of the advances that have been 
made in the field of AD research from the beginning of the 20th century until now. 
Original 1907 report by Dr. Alzheimer had identified key morphological diagnostic criteria for AD 
diagnosis which are still valid today: neurotic plaques and neurofibrillary tangles. By mid-1940s a 
significant body of work describing AD had been published in medical journals which prompted one of the 
first literature reviews on the disease. In 1948, R. D. Newton published a comprehensive analysis on the 
state of AD field in “The journal of mental science” (Newton, 1948). This paper is of interest, as it was the 
first one to acknowledge that AD may occur “at any age” [sic]. Newton presented evidence that the rate of 
cognitive decline occurring in AD varies between patients. The author described that the term “Alzheimer 
Disease” was used when the disease occurred at a relatively young age (now called early-onset AD). When 
it occurred during old age with rapid progression, it was called “senile dementia”, and simply “senility” 
when the rate of cognitive decline was slow (both conditions are referred to as sporadic AD now). In order 
to suggest better terminology, Newton proposed to refer to AD as “Alzheimer’s dementia”, a term which 
is still frequently used in modern literature. 
In the decades that followed, no significant progress was made in identifying AD etiology until late 1970s 
-early 1980s. By that time, a number of theories as to the origins of AD had been proposed. These implicated 
autoimmunity, aluminium toxicity and infection by “slow virus” [sic] (Deakin, 1983). Unfortunately, none 
of these could account for the full spectrum of confirmed AD cases. One theory that did emerge however, 
became the subject of intensive research effort. In 1983, the “cholinergic hypothesis” became the dominant 
force in AD field (J. T. Coyle, Price, & DeLong, 1983). According to this view, selective denervation of 
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acetylcholine-releasing neurons, whose cell bodies are localized to the basal forebrain, may occur in AD. 
These cholinergic neurons innervate the cortical areas and related structures, especially the regions related 
to cognition and memory. It was suggested that cortical amyloid plaques primarily cluster around the 
cholinergic terminals, thus leading to retrograde degeneration of the related neurons and cognitive decline. 
The importance of this hypothesis cannot be overstated and is evidenced by the number of citations Coyle, 
Price and DeLong paper has received (over 2900 as of September 2015). Recent evidence suggests that 
cholinergic hypothesis clearly has its flaws. However, very few things in science are sufficiently “polished” 
when first proposed. An excellent review by Antonio Contestabile on the history of the cholinergic 
hypothesis points towards the advances this theory led to in AD research (Contestabile, 2011). 
The history of AD research from that era will not be complete without mentioning some of the claims which 
are still being made today based on very limited scientific proof. Aluminium exposure hypothesis is a prime 
example. Aluminium as a possible trigger for AD was first described in mid-1960s (Klatzo, Wisniewski, & 
Streicher, 1965; Terry & Pena, 1965), and the hypothesis was under investigation by mainstream science 
all the way until mid-1980s. Original findings described cognitive decline in rabbits exposed to aluminium 
salts, together with what appeared to be cerebral neurofibrillary tangles. It is worth noting that the 1965 
paper was in essence an accidental discovery, as aluminium was used as an adjuvant for immunizing the 
rabbits for antibody production. In the years that followed, none of the studies linking aluminium to AD 
were independently reproducible (reviewed by (Munoz, 1998)). Thus, the hypothesis was abandoned 
decades ago based on the lack of scientific evidence. Yet, despite the absence of verifiable claims, the 
aluminium hypothesis remains popular in the general public minds (Lidsky, 2014). In fact, a small number 
of articles were still being accepted for publication in scientific journals as late as 2014, which seemingly 
support this claim (Kawahara & Kato-Negishi, 2011; Tomljenovic, 2011; Walton, 2014). While it is not a 
purpose of this thesis to “debunk” questionable theories of the origins of AD, I would like to cite verbatim 
the last 2 sentences of the abstract of the Walton paper and let the reader make an informed decision: “AD 
is a human form of chronic aluminum neurotoxicity. The causality analysis demonstrates that chronic 
aluminum intake causes AD”. These conclusions are in stark contrast with a similar meta-analysis published 
in 2015: “The findings of the present meta-analysis do not support a causative role of aluminum in the 
pathogenesis of AD” (Virk & Eslick, 2015).  
In 1985, Wong and co-authors (Wong, Quaranta, & Glenner, 1985) have determined that the amyloid beta 
peptide is the main component of neuritic plaques present in the brain of AD patients. Shortly after, Nukina 
and Ihara (Nukina & Ihara, 1986) identified Tau protein as a principal constituent of paired helical filaments 
(PHF) and neurofibrillary tangles (see Fig. 1). These findings paved the way for a number of key discoveries 
which occurred in the years that followed.  
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Early 1990s heralded a new era in AD research. 1992 is widely considered as the year when Hardy and 
Higgins (J. A. Hardy & Higgins, 1992) have fully solidified an “amyloid cascade” hypothesis. Despite the 
claims of John Hardy that he was “one of the two (inaccurately) credited with originating the amyloid 
hypothesis” (J. Hardy, 2009), John Hardy is still considered as one of the “Godfathers” of the idea. The 
amyloid cascade hypothesis states that the amyloid peptide is key to AD pathology. The hypothesis assumes 
that beta amyloid deposition produces senile plaques, leading to neurofibrillary tangle formation, which 
cause the death of neurons leading to cognitive decline. Since then, significant research efforts on the part 
of academic labs and the pharmaceutical industry have largely focused on the amyloid cascade as the 
principal target for AD treatment. Unfortunately, none of the molecules that reached Phase II and III clinical 
trials targeting this pathway have proven to be more effective than placebo at treating AD (reviewed by  
(Schneider et al., 2014)). Nevertheless, it is abundantly clear that the amyloid cascade hypothesis has 
significantly furthered our understanding of the underlying disease pathology. 
“Vascular hypothesis”, which emerged in 1993 (J. C. de la Torre & Mussivand, 1993), proposed that 
abnormalities in brain microvasculature, occurring as a result of aging, may contribute to AD. It was 
suggested that beta amyloid may cause accelerated degeneration of brain capillaries. Disturbances in the 
cerebral blood flow that follow, are likely to result in reduced delivery of both the glucose and oxygen to 
cerebral neurons. Energy deprivation and the resultant ischemia produces tissue damage which causes 
inflammation and may eventually result in neurofibrillary tangle formation. Some elements of this 
hypothesis parallel the changes described by “oxidative stress”, “mitochondrial cascade” and 
“neuroinflammation” hypotheses (see pages 19, 20 and 21). 
Another major breakthrough which occurred during the late 1980s and early 1990s was the identification 
of genetic components which contribute to the disease state. Significant progress was made in the discovery 
of susceptibility genes for a plethora of conditions. AD was no exception. By 1995, mutations in 
Apolipoprotein E (APOE), presenilin 1 and 2 (PS1 and PS1) and amyloid precursor protein (APP) were 
definitively linked to AD pathology (Pericak-Vance & Haines, 1995). It is important to note at this point, 
that mutations in APP, PS1 and PS2 all result in aberrant processing of the amyloid precursor protein (Fig. 
1), leading to amyloid plaque formation and to the development of an early-onset AD (also known as 
familial AD or FAD). The role of APOE mutations is not entirely clear even today, however, a particular 
allele of APOE (ε4) is a known risk factor for the development of late-onset AD.  This was an exciting 
period in the field of AD research, as the possible cure seemed within easy reach. But, and such is the story 
of Alzheimer´s, the disease proved to be a much tougher nut to crack as was anticipated. 
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Figure 1. (Top part) A mechanism thereby Aβ is produced from APP: Under physiological conditions, APP 
is preferentially cleaved by α-secretase complex, which cuts the molecule in the middle of the Aβ fragment, 
thus not allowing the formation of Aβ. In a pathological state (amyloidogenic route), APP is sequentially 
cleaved first by β- and then by γ-secretase complexes, resulting in the generation of the amyloid beta 
peptides and the AICD. γ-secretase can cut APP at multiple residues resulting in the production of either 
Aβ (1-40) or Aβ (1-42). Aβ (1-42) is considered a more pathogenic form of the peptide. Mutations in the 
PS1, PS2 (proteins which form an integral part of γ-secretase complex) and APP favor Aβ (1-42) 
production. (Bottom part) A mechanism thereby NFTs are generated from hyperphosphorylated tau 
protein: Tau proteins physiological role is to stabilize microtubules. A process which is regulated by the 
phosphorylation state of the protein. Tau hyperphosphorylation results in the formation of soluble tau 
aggregates, which are eventually deposited as insoluble neurofibrillary tangles (see section 3.5 of the 
Introduction).  *AICD: amyloid precursor protein intracellular domain; NFT: neurofibrillary tangles 
composed of paired helical filaments **Adapted from (Götz & Ittner, 2008)  
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Once a link between brain amyloid beta peptide deposits and AD was clearly established, the scientific 
community attempted to identify molecular mechanisms which could explain neurodegenerative processes. 
Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity was among the first to emerge 
(Pollard, Arispe, & Rojas, 1995). At its core, it was suggested that aberrantly processed beta amyloid 
peptides are capable of forming distinct (and unnatural) Ca2+-conducting ion channels within neuronal 
membranes which could cause increased intracellular Ca2+ concentrations, thus disrupting neuronal 
homeostasis and causing excitotoxicity (neuronal damage and/or death due to overstimulation). This 
hypothesis faded into obscurity fairly quickly. However, the role of excessive intracellular Ca2+ was 
explored from another angle by Olney and colleagues (Olney, Wozniak, & Farber, 1997) who proposed 
that N-methyl D-aspartate receptor (NMDAR) signaling may be disrupted in AD (“excitotoxic 
neurodegeneration hypothesis”). NMDAR constitute a major class of excitatory ligand-gated ion channels 
in the brain. These receptors are primarily activated by the endogenous neurotransmitter glutamate (Glu). 
Upon activation, Ca2+ influx is allowed via the open channel pore. Both the Glu and the NMDAR are 
ubiquitous in mammalian brain, with NMDAR mainly localized to the post-synaptic membrane of 
excitatory synapses (Jones & Baughman, 1991). NMDAR signaling contributes to neuronal differentiation, 
synaptic plasticity and long-term potentiation. These receptors also play a role in glutamate neurotoxicity 
(Greenamyre & Porter, 1994). So how exactly does the NMDAR-mediated excitotoxicity occur? The short 
answer is that we still do not know. What we do know, is that excessive synaptic release of glutamate may 
overwhelm endogenous Ca2+ homeostasis regulation, leading to a significant influx of Ca2+ ions post-
synaptically, by mechanisms which involve not only NMDAR but other receptors as well, beyond the scope 
of this thesis. Intracellular Ca2+ overload ultimately leads to neuronal death, either by apoptosis or necrosis, 
depending on the severity of the stimulus. During the course of researching materials for this dissertation, 
the most comprehensive and reliable review on calcium excitotoxicity in neurodegeneration I was able to 
find was published in 2003 (Arundine & Tymianski, 2003). To go back to the original “excitotoxic 
neurodegeneration hypothesis”, one conclusion presented by Olney and colleagues is particularly 
significant. Briefly, the authors point out that under the circumstances of acute CNS injury, including brain 
trauma and stroke, NMDAR are hyper activated, which causes severe Ca2+ excitotoxicity. In the case of 
AD, however, this appeared to not be the case, because basal NMDAR activity was reduced in the brain in 
response to normal ageing (this observation is of particular interest when looked at from the perspective of 
the “synaptic dysfunction” hypothesis discussed on page 24). The most important finding of the study was 
that this condition of hypo-activation seemed to result in increased sensitivity of the receptors towards 
subsequent stimuli. That is to say, in advanced age, even weak agonist activity is capable of producing 
exaggerated Ca2+ influx. Therefore, in individuals suffering from sporadic AD or similar neurodegenerative 
disorders, chronic exposure to low-grade glutamatergic activation (by predisposing factors which were 
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unknown at the time) may produce progressive neurodegeneration as a result of continuous NMDAR-
mediated excitotoxicity. In the later part of the introduction (page 33), I will go back to the concept of how 
chronic exposure to stimuli at levels which are generally considered insufficient to produce a biological 
response, may have a measurable impact on AD pathology. As a side note, recent evidence indicates that 
neuronal Ca2+ metabolism is indeed disrupted in AD, however, some authors claim that disturbances in 
Ca2+ signaling may also be neuro-protective under some circumstances (reviewed by (Supnet & 
Bezprozvanny, 2010)).  
Another hypothesis which emerged in 1990s is the so-called “oxidative stress hypothesis”. The fact that the 
brain is an organ with a high oxygen consumption rate coupled to its elevated lipid content and the relatively 
low abundance of antioxidant enzymes when compared to other tissues, gave credence to this hypothesis.  
Proposed by Markesbery (Markesbery, 1997), it was largely based on accumulated body of evidence 
indicating the presence of significant oxidative stress in the brains of AD patients. This author provided 
ample data to support the claim. First of all, Markesbery cited elevated levels of base metals including iron, 
aluminium and mercury which were present in the brains of diseased patients. Trace amounts of these 
elements were known to produce free radicals in multiple tissues. Second, evidence was presented that lipid 
peroxidation levels were increased, and this was accompanied by a simultaneous decrease in 
polyunsaturated fatty acids (PUFA) in AD brain. PUFA are a critical component of the phospholipid 
membrane and allow for additional flexibility and fluidity of cellular membranes (Rajamoorthi, Petrache, 
McIntosh, & Brown, 2005). PUFA are highly oxidizable and the reduction in their levels is indicative of 
free radical damage. In addition, increased protein and DNA oxidation in AD brains was demonstrated in 
literature analysis performed by Markesbery. Furthermore, the presence of advanced glycation end-
products (AGEs) and related molecules was also described in affected tissue samples. Cerebral energy 
metabolism was apparently reduced as well. Last, but not least. Markesbery pointed out that the beta 
amyloid aggregates have the capacity to generate free radicals on their own. It is of little wonder then, that 
this hypothesis provided additional stimuli for significantly increased funding of AD research on a global 
level. 
Due to the apparent presence of oxidative stress in AD pathology, researchers turned their attention towards 
mitochondria. These organelles are a central source of cellular adenosine triphosphate (ATP), the principal 
energy “currency” for cellular metabolism. Deficiencies in the mitochondrial Electron Transport Chain 
(ETC) may cause alterations in the processes of oxidative phosphorylation (OXPHOS complexes), leading 
to production of highly reactive free-radical superoxide, a major source of intrinsic oxidative stress. One of 
the first papers which linked mitochondrial DNA (mtDNA) mutations to sporadic AD cases was published 
by Swerdlow and coworkers in 1997 (R H Swerdlow et al., 1997). Authors utilized a cytoplasmic hybrid 
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(cybrid) model to demonstrate that mutations in mtDNA are largely responsible for defects in cytochrome 
c oxidase (COX or Complex IV) enzyme, one of the key enzymes in the ETC pathway (cybrids are created 
by transferring donor mtDNA to neuronal-like cells which are depleted of mitochondria in vitro). In that 
study, cybrids generated from the samples of AD patients demonstrated decreases in complex IV activity, 
coupled with increased production of reactive oxygen species (ROS) and increased  antioxidant enzymes 
(AOE) activity. A comprehensive review (citing over 270 papers) evaluating the role of mitochondria in 
neurodegenerative diseases, including AD, was published in 1999 (Cassarino & Bennett, 1999).  It took 
additional 5 years to recapitulate existing knowledge and to formulate a “mitochondrial cascade hypothesis” 
of AD (Russell H Swerdlow & Khan, 2004). 
By 2004, it became evident that “amyloid cascade hypothesis” cannot fully explain the pathological features 
of the disease. Even though the case of Auguste Deter is a clear example of FAD (due to PS1 mutation), 
FAD represents only a tiny proportion of patients, with the vast majority suffering from the sporadic (late-
onset) form of the disease. Patients with late-onset Alzheimer do not have the mutations which result in 
increased beta amyloid production. Furthermore, a significant number of non-demented aged population 
presents with cerebral amyloid plaques discovered in post-mortem analysis. The “mitochondrial cascade 
hypothesis” attempts to identify the distinct pathological hallmarks of the sporadic form of AD compared 
to FAD, and suggests that mitochondria play a key role in the development of late-onset pathology. The 
hypothesis can be broken down into the following constitutive parts: 1) Basal mitochondrial ROS 
production depends on inherited polymorphic variations in mtDNA which affect the expression levels and 
activity of key enzymes participating in ETC (OXPHOS complexes); 2) Higher basal ROS production rates 
cause more rapid accumulation of de novo somatic mtDNA mutations; 3) These accumulated mutations 
result in additional reductions in OXHPOS metabolism, triggering further increases in ROS production. 
Once ROS levels reach a certain threshold, a three-part compensatory mechanism is activated. The authors 
termed this series of events as a “reset” (1), “remove” (2) and “replace” (3) response. During the first part 
of the sequence the system is “reset”, whereby excess ROS in terminally differentiated neurons cause a 
shift in cellular redox balance, leading to aberrant activation of the plasma membrane oxidoreductase 
system. Resulting increase in plasma membrane ROS favors increased amyloid beta peptide production 
from the APP, thus contributing to amyloid plaque formation. The following “removal” phase is the 
elimination of the most affected neurons by apoptosis. These are the neurons in which ROS levels remain 
abnormally high and/or OXPHOS metabolism is significantly diminished. In the final “replacement” part 
of the sequence, an attempt is made to replace the destroyed neurons. It is important to note that 
mitochondrial homeostasis is also likely disrupted in neurons which are supposed to replace the post-
apoptotic cells. However, the levels of ROS and OXPHOS perturbations are not sufficiently high in these 
neurons to trigger apoptosis. The exact molecular mechanism whereby “replacement” occurs is at the crux 
INTRODUCTION 
21 
  
of “mitochondrial cascade hypothesis”. The authors suggest that anaerobic glycolysis is preferentially 
activated in neurons in which OXPHOS metabolism is reduced. Apart from ROS generation, this also 
initiates hypoxic signaling pathway which activates mitotic cell-cycle re-entry program in neurons capable 
of proliferation. During this process, tau (hyper)-phosphorylation and neurofibrillary tangle formation may 
take place, providing evidence that both the tauopathy (in “replace” phase) and amyloid beta peptide 
production (in “reset” phase) are dependent on abnormal mitochondrial signaling. Another interesting 
observation made by the same authors is that it appears that the proliferation process is never completed 
(possibly due to the lack of ATP under these circumstances). And, therefore, the damaged neurons are never 
truly replaced (Russell H Swerdlow, Burns, & Khan, 2010; Russell H Swerdlow & Khan, 2004). As 
mentioned earlier, both the “mitochondrial cascade” and the “oxidative stress” hypotheses share some 
elements with the “vascular” hypothesis. In particular, cerebral ischemia results in increased oxidative stress 
coupled with reduced OXPHOS metabolism. Therefore, these hypotheses are not mutually exclusive. 
The “two-hit hypothesis” (Zhu, Raina, Perry, & Smith, 2004) is similar to the “mitochondrial cascade 
hypothesis”, however it describes AD pathology from a different angle. The “mitochondrial cascade 
hypothesis” suggests a sequence of events starting from mitochondrial defects causing increased ROS 
generation, which ultimately result in disrupted mitotic signaling. In case of the “two-hit hypothesis”, 
authors acknowledge that both oxidative stress and cell-cycle deficiencies are early events in AD pathology. 
The key difference is the suggestion by the authors that either the oxidative stress or dysregulated mitotic 
signaling may act as independent triggers of the AD pathology. Once the disease process is initiated, 
however, it is claimed that the presence of both of those triggers is required for disease propagation (hence 
the name “two-hit”). The idea behind the hypothesis is that the neurons may be capable of adapting to a 
situation in which a single insult is present, but are not sufficiently equipped to respond to multiple 
simultaneous homeostasis disruptions. In case of AD, either one of the “hits” by itself, be it cell-cycle 
defects or oxidative stress, is not sufficient to cause full-blown AD. But, once one of the “hits” is already 
present, the whole system becomes vulnerable to the effects of the second “hit”. This model is quite elegant, 
with authors claiming that it can be applied to multiple neurodegenerative diseases, and not just AD. 
Immune system, particularly innate immunity and inflammatory responses are additional factors which 
contribute to AD pathology. All the way until the mid-1980s, it was considered highly unlikely that 
inflammatory processes could occur within the brain due to the phenomenon of “immune privilege”. The 
concept of “immune privilege” is based on the observations that immune-mediated inflammation and 
allograft rejection rates are significantly reduced in some organs including the brain. According to 
Niederkorn (Niederkorn, 2006), the phenomenon was described in medical literature as early as 1873 
(Graefes, 1873), with the actual term “immune privilege” created in 1948 (Medawar, 1948). It is thought 
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that the suppression of inflammatory responses in the CNS provides a significant evolutionary advantage.  
Because of the importance of the brain to the survival of the whole organism and its relative lack of 
regenerative capacity, immune-mediated inflammatory responses in this organ could be devastating, so it 
makes sense to protect the brain from the effects of generalized inflammation. It was thought that such 
protection is provided by means of endothelial blood-brain barrier (BBB), which was considered to be 
impenetrable to the cells of the immune system. Thus, the prevailing view in the 1980s was that the apparent 
signs of inflammation in the brains of deceased AD patients were likely artifacts and did not reflect the 
disease pathology. This changed with the publication of a series of papers which first described that 
activated T cells are capable of crossing BBB with relative ease (Wekerle, Linington, Lassmann, & 
Meyermann, 1986). Once across the barrier, these activated T cells were able to interact with the glial cells, 
particularly the astrocytes, by releasing a number of chemical factors (Wekerle, Sun, Oropeza-Wekerle, & 
Meyermann, 1987). In addition, it was demonstrated that severe systemic inflammation (induced by a graft 
versus host disease) resulted in T lymphocyte infiltration into the CNS (Hickey & Kimura, 1987) with the 
apparent involvement of perivascular microglial cells (Hickey & Kimura, 1988). These findings resulted in 
the re-evaluation of a possible role of immunity in CNS disorders including AD. In retrospect, it is now 
relatively easy to understand that beta amyloid plaques, neurofibrillary tangles and neurodegeneration could 
result in neuroinflammation. After all, in peripheral tissues inflammation is frequently caused by tissue 
damage and the chronic presence of inert foreign materials. The classical pathological features of AD could 
easily be such triggers in the CNS. During the 1990s, a large number of studies attempting to identify 
molecular mechanisms of neuroinflammation in AD were published. A working model which organized 
available knowledge of inflammatory pathways in relation to AD was presented by a Neuroinflammation 
Working Group in 2000 (Akiyama et al., 2000). It is notable that of nearly 700 studies which were cited in 
that article, the vast majority of papers were published during the 1990s. What emerged is a highly complex 
regulatory mechanism whereby immune system reacts to disease pathophysiology. To provide even a brief 
overview of all the molecular networks involved in neuroinflammation will take many pages, and is beyond 
the scope of this thesis. I would just like to point out that one of the critical findings of the study was that 
neuroinflammation in AD appeared to originate from within the CNS itself, with little involvement of 
peripherally derived monocytes and lymphocytes.  
The biological pathways linking immune response to AD continue to be an area of active research. While 
it is clear that neuroinflammation does indeed occur in AD, the fundamental question remains: is it the 
cause or the consequence of the underlying pathology? At first, it appeared that the inflammatory response 
is a result of amyloid plaques, neurofibrillary tangles, and nerve damage (reviewed by (Akiyama et al., 
2000; Heneka, Kummer, & Latz, 2014)). However, in recent years it was suggested that neuroinflammation 
may occur prior to the disease development and may actually lead to accelerated plaque and tangle 
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formation. Even if occurring in later disease stages, it may exacerbate the disease phenotype. Furthermore, 
inflammation can actually be a beneficial response, which slows down disease progression (Wyss-Coray, 
2006). It is now recognized that in virtually all diseases that affect CNS, immune system plays a role. The 
key difference between neurodegenerative diseases, such as AD, and neuroinflammatory diseases, such as 
multiple sclerosis (MS), is the type of inflammation each of these diseases produces. In case of MS, 
inflammation is driven largely by the adaptive immune response, whilst in AD, innate immunity appears to 
be the primary contributor. In AD-driven inflammation, intrinsic CNS-resident immune cells (including 
microglia, perivascular myeloid cells and astroglia) appear to play a principal role (Heppner, Ransohoff, & 
Becher, 2015). However, peripheral/systemic inflammation caused by obesity, metabolic syndrome and 
type 2 diabetes mellitus (T2DM) have also been identified as risk factors for AD development (Takeda et 
al., 2010; Thaler et al., 2012).  
A possible connection between insulin signaling molecules and AD was described by Kurochkin and Goto 
in 1994 (Kurochkin & Goto, 1994). The authors identified Insulin Degrading Enzyme (IDE) as being very 
efficient at clearing intracellular beta amyloid peptides (Aβ(1-40)). IDE is a highly selective protease 
responsible for cleaving (and inactivating) small peptides, notably insulin and glucagon. Authors concluded 
that defects in IDE may result in excessive production of beta amyloid, thus contributing to amyloid plaque 
generation. That particular study linked AD to insulin signaling mostly in name alone. Just because IDE 
was originally identified as an insulin protease was clearly not enough to suggest that its amyloidolytic 
activity is also related to insulin metabolism. One of the first reports which confirmed that deletion of IDE 
is capable of causing both chronic elevation of cerebral amyloid beta levels and hyperinsulinemia coupled 
with impaired glucose tolerance in vivo, was performed by Farris and colleagues (Farris et al., 2003). In a 
follow-up study by the same group, authors point out that naturally occurring, partial loss-of-function 
mutations in IDE protein, are sufficient to induce a diabetic phenotype in rats together with simultaneous 
reductions in beta amyloid clearance in the brain (Farris et al., 2004). In the same year, seminal work was 
published by researchers at Mayo Clinic (2 of the co-authors of Farris paper were also from the Mayo 
Clinic, but in a different group) who reported increased risk for T2DM development in AD patients (Janson 
et al., 2004). Strikingly, either impaired fasting glucose (IFG) or T2DM was detected in 81% of patients 
with AD (42% in the control group). In this community-based controlled study, called the Mayo Clinic 
Alzheimer Disease Patient Registry (ADPR), 100 patients with AD were compared to 138 control subjects 
with the aim of evaluating T2DM prevalence in elderly AD population (mean age 79±9 years). Apart from 
the clearly increased risk of metabolic perturbations in AD, these patients presented with significantly 
elevated pancreatic islet levels of beta amyloid. In contrast, in subjects with T2DM who did not have AD, 
cerebral beta amyloid levels were not increased. When both T2DM and AD were detected, brain amyloid 
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deposition appeared to be correlated with the duration of diabetes. To my knowledge, this was one of the 
first large-scale human studies in which AD was linked to the peripheral insulin metabolism.  
A second line of evidence that impaired insulin signaling contributes to AD was published by Steen, de la 
Monte and coworkers (Suzanne M de la Monte & Wands, 2005; Steen et al., 2005) who demonstrated that 
molecules involved in the insulin pathway are endogenously expressed and downregulated in AD brain. 
Significant hippocampal levels of mRNA transcripts of insulin (INS), insulin-like growth factors I and II 
(IGF1 and IGF2) and their related receptors (INS-R, IGF1-R and IGF2-R), were detected in post-mortem 
human tissue. In the hippocampi of AD patients, reduced expression was detected in all of these genes apart 
from IGF1 (which remained unchanged), when compared to the control group. Furthermore, a number of 
molecules involved in insulin signaling downstream of the INS-R were also affected in diseased brain. For 
example, mRNA levels of insulin receptor substrate (IRS), IRS-associated phosphatidylinositol 3–kinase 
(PI3K) and AKT (also known as protein kinase B – PKB) were reduced, with the concomitant increase in 
glycogen synthase kinase-3β (GSK-3β) mRNA. All of these proteins form a crucial component of the 
hormone-mediated growth and survival signal-transduction pathways and are known to be dysregulated in 
diabetes. As all of these changes were detected directly in the brain, and especially in the areas known to 
be most affected by senile plaques and neurofibrillary tangles, the authors proposed a hypothesis that AD 
may resemble what they termed “Type 3 Diabetes”. i.e AD is a form of brain-specific diabetes. 
In the very same year, “synaptic dysfunction” hypothesis was proposed. Curiously, the term was coined by 
Rudolph E. Tanzi of Harvard University (Tanzi, 2005) in a comment to a paper published in the same issue 
of Nature Neuroscience by authors not affiliated with Harvard University (Snyder et al., 2005). What 
Snyder and colleagues observed, was the deregulation of synaptic plasticity due to NMDA receptor 
endocytosis caused by beta amyloid administration, resulting in the inhibition of excitatory 
neurotransmission. Among the key findings was the suggestion that amyloid beta oligomers, well before 
they reach the stage of amyloid plaques, are capable of inducing synaptic dysfunction in in vitro cultures 
of mouse neurons. As synaptic failure, and particularly reductions in Long-Term Potentiation (LTP), are 
associated with memory deficits (Selkoe, 2002), a conclusion was made that NMDAR-dependent synaptic 
deficiency may be a driver for future pathology. Because this hypothesis is clearly linked to NMDAR 
signaling abnormalities, these events, in my opinion, should be compared to the postulates of the 
“excitotoxic neurodegeneration” hypothesis, especially the part relating to the reduced basal NMDAR 
activity (see page 18). 
One of the most recently introduced hypotheses is termed “dendritic hypothesis” and is partly based on 
“synaptic dysfunction” hypothesis (Cochran, Hall, & Roberson, 2013). Since the identification of synapse 
as a possible site of AD-related damage, additional scientific effort was put towards identifying the role the 
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dendrites play post-synaptically. The authors point out that dendritic abnormalities have long been observed 
in AD-affected brain. However, technological limitations have reduced researcher`s ability to study changes 
in dendrites in detail. While dystrophic neurites, reduced dendritic complexity and dendritic spine loss are 
all documented features of AD, it is only recently that we are beginning to understand the underlying 
molecular mechanisms (Cochran provided an excellent overview of the published data on the subject in the 
2nd section of the paper, so I will refrain from providing source citations in this part of the introduction). In 
support of the dendritic role in AD pathogenesis, authors offer evidence that amyloid beta peptide is capable 
of direct post-synaptic binding to dendrites, can affect dendritic Ca2+ channel functions (beyond the scope 
of this introduction, but refer to “ion channel” and “excitotoxic neurodegeneration” hypotheses on page 18, 
as well as section 3.6 on page 43), and that Tau protein can potentially be targeted (or mis-targeted) towards 
the dendrites. Altogether, the data suggest that dendrites may be an additional factor contributing to AD. 
What the brief and by no means exhaustive historical overview of the disease illustrates, is that over a dozen 
hypotheses intending to explain AD etiology have been proposed over the years. It became abundantly clear 
that AD is a highly complex disorder involving multiple biological pathways. It is also of little wonder then, 
that the pharmaceutical interventions attempted to-date have largely failed in innumerable clinical trials. In 
the following section of this introduction, I will attempt to summarize the clinical aspects of AD treatment, 
and to relate the pharmacological approaches to the disease. As in the first part of the introduction, the 
chronological timeline will be followed whenever possible.
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3. PHARMACOLOGICAL APPROACHES TO ALZHEIMER DISEASE TREATMENT 
In the 100+ years since the formal description of Alzheimer disease, a large number of treatment strategies 
has been attempted with mixed results. The primary goal of any pharmacological intervention is to improve 
the cognitive and behavioral symptoms of the disease. There are only four compounds currently approved 
for AD treatment on the market. 3 of these are acetylcholinesterase inhibitors, and one is an NMDAR 
antagonist. In this section, I will provide a brief overview of the pharmacotherapies targeting AD, loosely 
grouped according to the principal biological route affected by these molecules. The first 2 subsections will 
cover existing treatments, with the rest of the material referring to compounds which are investigated for 
their possible role in improving AD symptomatology. A summary of molecules discussed in section 3.1 is 
provided in tabulated form in Table 1 (page 32), while Table 2 (page 46) is a list of chemicals and clinical 
trial IDs for the compounds mentioned is sections 3.3-3.8. 
3.1 Cholinergic system 
Compounds which fall into this category all aim to restore cholinergic neurotransmission with the rationale 
for their use provided by the “cholinergic hypothesis” (see page 14). Acetylcholine (ACh) biosynthesis 
occurs pre-synaptically from the precursors Acetyl-CoA and choline and requires an enzyme choline 
acetyltransferase (CAT). Upon release, ACh is rapidly metabolized post-synaptically into acetate and 
choline by acetylcholinesterase (AChE). Thereafter, choline is transported back into the terminal (Fig. 2) 
(Purves et al., 2001). With the idea that cholinergic neurotransmission is disrupted as a result of AD 
pathology, this mechanism suggests a number of possible drug targets within this pathway. One of the 
earliest treatments which reached the clinical trials stage in humans was with lecithin. Lecithin is a complex 
phospholipid which is a major dietary source of choline. It was originally thought that by increasing the 
dietary bioavailability of choline, cerebral levels of ACh would increase as well. Cochrane Reviews 
published an extensive analysis of randomized clinical trials in which the efficacy of lecithin in AD was 
measured. In the span of 25 years (from 1978-2003) a total of 12 independent clinical trials which passed 
the inclusion criteria were conducted. Unfortunately, none have reported any significant benefit of lecithin 
administration in AD (Higgins & Flicker, 2003). (Please note that even though the Cochrane Review was 
published in 2003, it has been revised in 2009 with no additional changes made to the paper). 
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Figure 2. Acetylcholine metabolism in cholinergic nerve terminals. The synthesis of acetylcholine from 
choline and acetyl CoA requires choline acetyltransferase. Acetyl CoA is derived from pyruvate generated 
by glycolysis, while choline is transported into the terminals via a Na+-dependent transporter. After release, 
acetylcholine is rapidly metabolized by acetylcholinesterase and choline is transported back into the 
terminal. *Reproduced from (Purves et al., 2001) 
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Due to the very high catalytic activity of AChE (about 5000 ACh molecules per each AChE molecule per 
second) (Purves et al., 2001), AChE inhibition is an obvious potential target to increase ACh levels at the 
synaptic cleft. Physostygmine, a compound with a phenyl carbamate nucleus, was the first AChE inhibitor 
(AChEI) to be tried as a treatment for AD in a clinical setting. A number of papers were published starting 
from 1978 which evaluated physostygmine for its potential in reducing cognitive decline in AD. By 1987, 
however, it emerged that physostygmine treatment was just as ineffective as lecithin, possibly due to its 
poor absorption, very short half-life and a narrow therapeutic index (reviewed by (Orgogozo & Spiegel, 
1987)). Nevertheless, research into physostygmine use in AD continued all the way until early 2000s, with 
some researchers attempting to overcome the half-life limitation by formulating extended-release oral forms 
of the compound. The possible use of physostigmine in the treatment of AD was also reviewed by Cochrane 
Reviews, with the latest update performed in 2008 (Coelho Filho & Birks, 2001). Of the 15 clinical trials 
identified, none demonstrated improved efficacy when compared to placebo. The authors reached an 
unequivocal conclusion that physostygmine use in AD is of purely historic interest at this point. 
Tacrine happened to be the very first pharmacological treatment ever to reach the market for AD.  This 
centrally-acting AChEI was approved by the FDA for this indication in the US in 1993 (Crismon, 1994). 
Tacrine exhibited significantly better pharmacokinetic (even though oral bioavailability was still low, and 
the half-life was just 3-6 hours) and safety profiles, when compared to physostygmine (Soares & Gershon, 
1995). Furthermore, the results of 12 major clinical trials which recruited over 2000 participants in total, 
have demonstrated modest improvement in the rates of cognitive deterioration in treated patients. However, 
most of these clinical trials were short-term, with the treatment length varying between just 3-12 weeks (In 
only 2 trials the treatment lasted 30 and 36 weeks) (reviewed by (Nawab Qizilbash et al., 1998)). Due to 
the lack of long-term efficacy data and the controversy surrounding the improvement in behavioral 
disturbances and the functional autonomy of the treated population (it was unclear if tacrine had any effect 
whatsoever on these parameters), it became clear that the clinical efficacy of tacrine was far from ideal. 
Furthermore, possible hepatotoxicity was an additional cause for concern. Some of these issues were 
addressed in a review paper by William K. Summers in 2000, who defended continuing use of tacrine in 
AD (Summers, 2000). However, that review can hardly be considered unbiased, as Dr. Summers is the 
original developer of the compound. A more recent and comprehensive analysis of clinical trials involving 
tacrine was withdrawn in 2007 for reasons which are unclear ((N Qizilbash, Birks, Lopez Arrieta, 
Lewington, & Szeto, 2007). Tacrine itself was discontinued in the US market in 2012 due to safety concerns 
and the availability of more modern AChEIs. 
A number of alternative compounds which are derivatives of tacrine were also considered as possible 
treatment options for AD. Velnacrine is just one example. In my opinion, velnacrine is worth mentioning 
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here because it illustrates the fact that the aminoacridines (a chemical class to which both tacrine and 
velnacrine belong) were widely recognized in the field for their hepatotoxicity potential even at the time of 
tacrine approval. In fact, velnacrine was developed with the specific purpose of reducing toxicity associated 
with tacrine treatment. A total of 4 clinical trials recruiting 899 patients were conducted with velnacrine. 
Unfortunately, the drug was not an improvement over tacrine in a clinical setting, and was just as toxic. As 
a result, FDA rejected the compound in 1994. Since then, no additional clinical trials with velnacrine as a 
treatment for AD were conducted (J. Birks & Wilcock, 2004). It is worth noting that there is currently 
renewed interest in developing new molecules which employ aminoacridine chemical structure as a basis 
for intelligent drug design (de Aquino, Modolo, Alves, & de Fatima, 2013; Minarini et al., 2013; Romero, 
Cacabelos, Oset-Gasque, Samadi, & Marco-Contelles, 2013). 
Just as tacrine was the first approved pharmaceutical treatment for AD in the US, donepezil was the first 
symptomatic medication to gain approval in the UK (in 1997). According to Wilkinson (Wilkinson, 1999), 
tacrine was never considered for approval by UK regulators due to its short half-life and potential 
hepatotoxicity. Thus, when the clinical data on donepezil started pouring in, the regulators were 
understandably interested. Donepezil does not belong to an aminoacridine chemical class and is instead a 
piperidine-based, potent and specific non-competitive and reversible AChEI. Among its most favorable 
features, when compared to tacrine, is a half-life of nearly 70 hours and the apparent lack of hepatotoxicity. 
From the bedside perspective, the results of 24 large-scale clinical trials with nearly 6000 participants 
confirmed that donepezil was effective in improving not only the cognitive symptoms, but also had positive 
effects on behavior and functional autonomy of treated patients (compare to the tacrine studies). In addition, 
this time around, most of the trials were of 12-24 weeks duration, with one study lasting a full 52 weeks, 
with the reported benefits of delayed cognitive loss being maintained over the entire treatment period. 
Unfortunately, the clinical benefits of donepezil are rather modest, to the point that clinicians sometimes 
fail to register significant improvements in patient well-being and the treatment itself is largely palliative 
(J. Birks & Harvey, 2006). Donepezil is, without a doubt, a widely used drug for the symptomatic AD 
treatment, a higher dose of which was recently approved for severe AD (as opposed to most treatments 
which target mild-to-moderate AD dementia). This particular point is of interest, because all of the other 
compounds mentioned here were considered for relatively early disease stages, where the cognitive decline 
and behavioral changes were already apparent and AD diagnosis was suspected, but the patient had not yet 
progressed to what is considered as terminal diagnosis. It was assumed that in very advanced stages of 
dementia, the cholinergic neurons were damaged beyond repair, and that the inhibition of AChE would be 
of little benefit. In fact it was demonstrated that donepezil may lead to measurable improvement even in 
such circumstances. A 2011 review summarizes these findings (Curiously, the drug information package 
inserts were cited as legitimate scientific references in this review; see references 3 and 4) (Sabbagh & 
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Cummings, 2011). In a more recent paper, the authors reached similar conclusions, but the article is sadly 
full of grammar and stylistic mistakes (Cheewakriengkrai & Gauthier, 2013). 
Rivastigmine is a phenyl carbamate derivative, just like physostigmine, however due to its pharmacological 
properties it is a much better drug candidate. As mentioned earlier, first carbamate derivatives suffered from 
poor bioavailability and a short half-life, while early aminoacridine compounds (prior to donepezil) were 
relatively toxic. Rivastigmine was one of the few compounds in the carbamate class which demonstrated 
improved CNS selectivity over physostigmine. As a result, potential toxicity and the side effects stemming 
from peripheral cholinergic inhibition were significantly reduced (Enz, Amstutz, Boddeke, Gmelin, & 
Malanowski, 1993). Rivastigmine gained approval for the treatment of mild-to-moderate AD in Switzerland 
in 1997 (“The Pharma Letter,” 1997), the drug has since been approved in over 80 countries including all 
the countries in the EU, Canada and the US. A recent Cochrane Review summarized the findings of 7 major 
clinical trials with rivastigmine which have cumulatively recruited 3450 AD patients (J. S. Birks, Chong, 
& Grimley Evans, 2015). The principal clinical outcomes were similar to donepezil treatment and include 
reduced rates of cognitive decline in patients with mild-to-moderate AD. As with other AChEIs, the benefits 
were relatively modest and did not halt disease progression, but only slowed it down. The incidence of 
adverse events was acceptable, with most side-effects directly related to cholinergic inhibition with some 
adverse reactions occurring in the gastrointestinal (GI) tract. It is noteworthy that all of the AChEIs 
mentioned in this section were originally formulated in oral form. Rivastigmine became the first molecule 
in this class to gain approval as a transdermal (TD) patch (initially for mild-moderate AD). This is very 
significant, as transdermal administration provides similar efficacy as the oral form, with concomitant 
reduction in side-effects, particularly GI-related ones. This property led to the first-ever approval of a TD 
medication for the treatment of severe AD by the FDA in 2013 (Amanatkar & Grossberg, 2014; Jeffrey, 
2013).    
Galantamine is the third and latest AChEI which is still approved for the treatment of mild-to-moderate AD 
in the US and elsewhere. Galantamine is different from other approved drugs in this class as it is only a 
weak AChEI compared to other compounds described earlier. In addition to blocking AChE, galantamine 
is also a positive allosteric modulator of nicotinic ACh receptors (J. Coyle & Kershaw, 2001).  In fact, the 
pharmacological properties of this alkaloid on acetylcholine signaling were described decades ago ((Ueda, 
Matsumura, Kimoto, & Matsuda, 1962) – this is the first article concerning galantamine pharmacology 
available in English language on Pubmed). Ueda and co-authors pointed out that AChE inhibition was 
approximately 100 times lower with galantamine, compared to physostygmine. Furthermore, the authors 
suggested that the effects of galantamine could not be attributed to AChE inhibition alone.  In the mid-
2000s, this hypothesis was validated and it was proposed that neuroprotection (and presumably clinical 
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benefits) afforded by all three of the currently approved drugs (donepezil, rivastigmine and galanatamine) 
may result from effects secondary to those of AChE inhibition  (Arias, Gallego-Sandín, Villarroya, García, 
& López, 2005). As mentioned earlier, nicotinic receptors may be involved, however there appears to be 
an additional pharmacological effect of galantamine treatment which is directly relevant to the work 
described in the current thesis. Ali and colleagues (Ali, El-Abhar, Kamel, & Attia, 2015) demonstrated 
improved oral glucose tolerance together with significant reduction in diabetic phenotype in a rat model of 
streptozotocine (STZ)-induced T2DM when the animals were treated with galantamine. To my knowledge, 
this is the first study which directly demonstrates that a centrally-acting anti-AD may be successfully 
utilized as an anti-diabetic agent. If these data can be reproduced by other authors, then this would give 
additional support to the “type 3 diabetes” hypothesis of AD.  
In summary, modulation of cholinergic signaling gave rise to the three pharmacological compounds 
(belonging to three different chemical classes) which are widely used as a treatment for AD. While AChE 
has long been considered a primary target for these drugs, the data described in this section suggest a more 
complex mechanism of action. An overview of the key features of the molecules mentioned here is provided 
in Table 1. 
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Table 1. A list of chemical entities which affect cholinergic signaling. All of the compounds presented 
above were considered as a possible treatment option for AD in human clinical trials. The formulas are 
taken from chemicalbook.com  
Compound Formula Chemical class MOA Approval (USA) Page
Lecithin
a complex phospholipid 
composed of choline, 
phosphoric acid, fatty acids 
and glycerol
dietary source 
of choline
never approved XXX
Physostigmine phenyl carbamate derivative AChEI never approved XXX
Tacrine aminoacridine AChEI
(mild AD)  1993 
discontinued: 2012
XXX
Velnacrine aminoacridine AChEI never approved XXX
Donepezil piperidine-based AChEI
(mild AD) 1996 
(severe AD) 2006
XXX
Rivastigmine phenyl carbamate derivative AChEI
(mild AD) 2000 
(severe AD - 
transdermal patch) 
2013
XXX
Galantamine
norbelladine-derived 
benzazepine
AChEI (mild AD) 2001 XXX
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3.2 Glutamatergic approach 
Disruptions in NMDAR signaling and the resultant excitotoxicity contribute to AD pathology (see 
“excitotoxic neurodegeneration hypothesis” on page 18). Adamantine derivative memantine is the only 
NMDAR inhibitor (NMDRi) used in the clinical setting for AD treatment (Danysz & Parsons, 2012). This 
drug is an uncompetitive NMDRi which exhibits voltage-dependency and rapid receptor blocking and 
unblocking kinetics. These pharmacological properties lead to a relatively good safety profile, with low 
likelihood of adverse drug reactions (ADRs) (Chen et al., 1992). In essence, memantine is capable of 
NMDAR antagonism, while still permitting physiological glutamatergic signaling, including in the 
processes of learning and memory (Parsons, Stöffler, & Danysz, 2007). As mentioned in section 2 (page 
19), NMDAR hypo-activation may increase the sensitivity of the receptors towards subsequent stimuli. 
Memantine may be capable of blocking exaggerated responses precisely under such conditions. 
Memantine was approved for treatment of mild-to-severe AD in 2002 in Europe and in 2003 in the USA. 
Cochrane Reviews (updated in 2006) had identified 12 clinical trials with memantine in various types of 
dementia that met the inclusion criteria. Each of these trials had recruited between 60 and 579 participants. 
The main conclusion reached by the authors is that memantine administration for periods of up to 6 months 
significantly improved the rates of cognitive decline in AD patients measured at up to 28 weeks post-
treatment (McShane, Areosa Sastre, & Minakaran, 2006). A more recent meta-analysis published in 2013 
(Yang, Zhou, & Zhang, 2013) reached similar conclusions. Unfortunately, the data presented in that 
manuscript appear to be rather unreliable. Authors claim to have used Cochrane Handbook in order to 
identify trials that met their inclusion criteria, with 20 mg/day memantine administration being one of those. 
In at least one of the cited studies, the actual daily dose of memantine was 28 mg/day (NCT00322153 – 
reference 36 of that paper); therefore that study should have been excluded. Considering that the number 
of included studies was only 12 (out of nearly 900 published papers analyzed by authors) this should not 
have happened. Furthermore, a number of studies were inappropriately cited and, for at least one study, the 
country where the trial was performed was incorrectly identified (Schmidt study (reference 30) was a single-
center trial performed in Austria, and not Australia as claimed by the authors). A 2014 meta-analysis 
summarized a total of 23 trials and 11024 patients with AD who were treated with any of the currently 
available drugs (donepezil, galantamine, rivastigmine or memantine). The authors conclude that each of 
these drugs significantly improves AD pathology, with memantine exhibiting better side-effects profile 
when compared to AChEIs (Tan et al., 2014). 
All in all, all 4 pharmacotherapies do lead to slight but significant improvements in patient health. However, 
none of these are capable of halting the course of cognitive decline or reversing disease progression. It is 
abundantly clear that better drugs are required. In the following sections, a brief overview of all the 
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additional approaches to AD treatment is provided. Unfortunately, none of the pharmaceuticals discussed 
below have been approved in human patients. 
3.3 Amyloidogenic route 
In the last two decades, the pharmaceutical industry has focused primarily on the amyloidocentric approach, 
devoting substantial resources to develop effective AD drugs. However, multiple failures of drug candidates 
in clinical trials have led researchers to question the feasibility of this strategy (Drachman, 2014). One 
possible reason for failure is a lack of biomarkers which could reliably identify AD in relatively early stages. 
It is entirely possible that the patients currently recruited for Phase III trials are in such advanced stages of 
AD that any attempted intervention is probably useless. Therefore, new diagnostic tools capable of early 
detection are sorely needed. In the meantime, there is still a number of novel treatments under development, 
which target the amyloidogenic route (see Fig.1 on page 17). In order to reduce Aβ generation from the 
APP, - and β-secretase inhibition and the potentiation of α-secretase activity have been considered.  
3.3.1 Inhibitors and modulators of β-secretase 
β-secretase enzyme complex participates in the initial stages of the amyloidogenic APP-processing 
pathway. The development of β-secretase inhibitors is a challenge because besides the APP, this complex 
has many more substrates. To give just one example, neuregulin-1, which is involved in the myelination of 
CNS axons and synaptic plasticity is a target of β-secretase (Chiang & Koo, 2014). Broad range of 
substrates can lead to significant side-effects, even if the specific inhibition of the enzyme is achieved. 
Nevertheless, E2609 (clinicaltrial.gov ID# NCT01600859), MK-8931 (NCT01739348) and LY2886721 
(NCT01807026 and NCT01561430) have all shown efficacy in reducing Aβ production by up to 80-90% 
in the cerebrospinal fluid (CSF) in humans. None of β-secretase inhibitors have reached the market so far 
(May et al., 2015; Vassar & Kandalepas, 2011; Yan & Vassar, 2014). 
3.3.2 Inhibitors and modulators of -secretase 
The -secretase complex is responsible for the final stage of amyloidogenesis, leading to the generation of 
Aβ(1-40) and Aβ(1-42). -secretase inhibition was initially considered a promising disease-modifying 
strategy. However, substrate promiscuity presents similar issues facing β-secretase inhibitors. Notch 
protein, responsible for regulating cell proliferation, development, differentiation, and cellular 
communication is one of the targets of the -secretase. Just as with the β-secretase inhibitors, off-target 
secondary effects are a major concern (Imbimbo & Giardina, 2011; Wolfe, 2012). 
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Semagacestat (LY450139) is a -secretase inhibitor that decreased Aβ levels in blood and CSF in humans. 
The clinical study results (NCT00762411, NCT01035138, and NCT00762411) which recruited over 3000 
patients, are an example of the worst possible outcomes. It was reported that semagacestat treatment was 
associated with the worsening of cognition and the abilities to carry out the activities of daily living (ADAS-
cog scale) in AD patients. Additional side effects included weight loss, increased incidence of skin cancer, 
and a higher risk of infection (Doody et al., 2013). Avagacestat is another -secretase inhibitor the 
development of which was discontinued as a result of a lack of efficacy (NCT00810147, NCT00890890, 
NCT00810147 and NCT01079819) (Dockens et al., 2012; Tong et al., 2012). 
Soluble -secretase modulators (SGSM) may, in theory, be developed in such a way as to avoid the adverse 
events associated with general enzyme inhibition. The goal of such treatments is to block APP processing 
without interfering with other signaling pathways like Notch (D’Avanzo et al., 2015).  
SGSM development began with the observation that several nonsteroidal anti-inflammatory drugs 
(NSAIDs) decreased Aβ(1-42) peptide levels in vitro and in vivo (Eriksen et al., 2003; Heneka et al., 2015). 
Examples of these drugs are ibuprofen, sulindac, indomethacin and flurbiprofen. The accepted mechanism 
of action (MOA) of NSAIDs is the inhibition of cyclooxygenase (COX) enzymes. While ibuprofen is a 
COX inhibitor, R-flurbiprofen (Tarenflurbil) is not, and its effects on the reduction of Aβ levels cannot be 
attributed to COX inhibition. Unfortunately, Tarenflurbil and Ibuprofen did not show efficacy for AD 
treatment in their respective clinical trials (Miguel-Álvarez et al., 2015; Pasqualetti et al., 2009). CHF5074, 
just like R-flurbiprofen, is an NSAID devoid of COX inhibitory activity. CHF5074 may inhibit Aβ 
production presumably by blocking -secretase complexes. Recent studies have reclassified this compound 
as a microglial modulator on the basis of its ability to reduce both amyloid burden and microglial activation 
(Ronsisvalle et al., 2014). Results from a Phase II trial in patients with Mild Cognitive Impairment (MCI) 
indicate that CHF5074 treatment leads to improvements of several cognitive measures and reduces 
inflammatory marker levels in the CSF (Ross et al., 2013). 
The idea that the long-term use of NSAIDs could confer some protection against AD generated some 
interest in NSAIDs as a treatment potentially useful for reducing Aβ(1-42) levels. However, negative results 
reported in clinical trials with NSAIDs suggest that this hypothesis requires further refinement (Miguel-
Álvarez et al., 2015). 
Another example of a possible -secretase modulator is NIC5-15, which is a naturally occurring molecule. 
NIC5-15, also known as pinitol, is a natural cyclic sugar alcohol (Pitt, Thorner, Brautigan, Larner, & Klein, 
2013). This compound supposedly modulates -secretase and is reportedly capable of reducing Aβ 
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production, while not affecting the substrate cleavage of Notch. No peer-reviewed data are available for 
this compound in human treatment, so any reported results should be considered as a forward-looking 
statements requiring rigorous scientific proof. However, it is claimed that the compound improves cognitive 
function and memory in preclinical models of AD neuropathology. If true, these data suggest that NIC5-15 
may be a suitable therapeutic agent for the treatment of AD for two reasons: a) it preserves Notch activity 
and b) also it is potentially an insulin sensitizer. Moreover, it is supposedly being investigated as an anti-
inflammatory agent because it may prevent microglia activation. Once again, these results have not yet been 
confirmed by independent researchers. A modest phase II trial of pinitol in AD patients has recently been 
completed (NCT00470418) with no results released into public domain. 
3.3.3 Inhibition of β-amyloid peptide aggregation 
Aβ peptide aggregates give rise to amyloid plaques. The following compounds were developed in order to 
prevent senile plaque formation.  
The only inhibitor of Aβ aggregation that reached Phase III trials is the 3-amino-1-propaneosulfonic acid 
(3-APS, Alzhemed, tramiprosate) (Aisen et al., 2011; Gauthier et al., 2009). This medication was designed 
to interfere with or antagonize the interaction of soluble Aβ with endogenous glycosaminoglycans. 
Glycosaminoglycans have been shown to promote aggregation of Aβ amyloid fibril formation and 
deposition (Gupta-Bansal, Frederickson, & Brunden, 1995). However, the disappointing results of the 
above mentioned clinical trial have led to the suspension of this compound in Europe. 
Colostrinin, a complex of proline-rich polypeptides present in ovine, bovine and human colostrum inhibits 
aggregation of Aβ and its neurotoxicity in cell assays, and improves cognitive performance in mice models 
(Janusz & Zabłocka, 2013). Although a phase II trial showed slight improvements in Mini Mental State 
Evaluation in patients with mild AD in a treatment period of 15 months, this beneficial effect was not 
maintained after another 15 months of continuous treatment (Bilikiewicz & Gaus, 2004). 
Scyllo-inositol (ELND005) is an oral amyloid anti-aggregation agent capable of reducing Aβ toxicity in the 
mouse hippocampus. 18-month long Phase II clinical trial with ELND005 was conducted in participants 
with mild-to-moderate AD. This dose-finding, safety and efficacy trial did not meet its primary clinical 
efficiency outcomes (S. Salloway et al., 2011). 
Clinical trials for AD treatment were also performed with metal chelating 8-hydroxiquinolines (8-HQ) 
compounds clioquinol and PBT2. While their mechanism of action is not completely understood, it is 
thought that these molecules block the interaction between the base metals and brain Aβ peptide (Matlack 
et al., 2014). It was suggested that increased levels of oxidative stress in the brain of AD patients may be 
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partially due to copper ions binding to Aβ, leading to metal-mediated generation of Reactive Oxygen 
Species (ROS). It was also hypothesized that 8-HQs may prevent Aβ aggregation while simultaneously 
restoring homeostasis in cellular levels of copper and zinc ions (Robert, Liu, Nguyen, & Meunier, 2015; 
Ryan et al., 2015; Wang et al., 2014). The results of the clinical trials with these compounds in AD are 
inconclusive (Faux et al., 2010; Jenagaratnam & McShane, 2006). 
3.3.4 Compounds which promote the removal of amyloid deposits and aggregates 
Another potential treatment option which is centered on the amyloidogenic pathway is to promote the 
clearance of existing amyloid aggregates and deposits. To achieve this, three different strategies have been 
evaluated: 
Activation of enzymes that degrade amyloid plaques: Aggregates and amyloid plaques are degraded by 
multiple proteases including neprilysin, insulin-degrading enzyme (IDE), plasmin, endothelin-converting 
enzyme, angiotensin-converting enzyme and metalloproteinases. Protein levels of these enzymes decrease 
in AD, which contributes to the formation and accumulation of Aβ (Baranello et al., 2015; Higuchi, Iwata, 
& Saido, 2005; Nalivaeva, Beckett, Belyaev, & Turner, 2012). Despite being an attractive strategy for 
developing disease-modifying drugs, no compounds with this MOA have ever reached advanced clinical 
development due to a lack of specificity. 
Modulation of β-amyloid transport between the brain and the peripheral circulation: Aβ transport between 
the CNS and the peripheral circulation is regulated by: 1) apolipoproteins, for example Aβ may be 
transported from the blood to the brain when it is bound to APOE (Giau, Bagyinszky, An, & Kim, 2015); 
2) low-density lipoprotein receptor-related protein (LRP-1), which increases Aβ outflow from the brain to 
the blood (R. Deane, Sagare, & Zlokovic, 2008); 3) receptor for advanced glycation end products (RAGE), 
which facilitates the transport of Aβ across the blood-brain barrier (BBB) (R. J. Deane, 2012). 
The goal of any treatment which is focused on this mechanism is to reduce cerebral amyloid load by 
attempting to restrict Aβ to the peripheral circulation. To this end, a number of different strategies have 
been proposed, notably the peripheral administration of LRP-1. However, the only drug candidates that 
have reached clinical stage are the inhibitors/modulators of RAGE. These include PF-0449470052, which 
failed in phase II trials, and TTP4000, with the Phase I trial completed in February 2013 (NCT01548430). 
The results of this trial have not been published.  
3.4 Anti-amyloid immunotherapy 
3.4.1 Active immunotherapy 
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Active immunotherapy is a strategy aimed to promote Aβ clearance with the objective of reducing the 
amyloid load in AD. Active immunization (vaccination) with either Aβ(1-42) (predominant form found in 
senile plaques) or other synthetic fragments has been successfully evaluated in transgenic mouse models of 
AD. Assays are generally based on the stimulation of B cells, T cells and immune responses through 
activation of the phagocytic capacity of microglia. Human tests were initially promising, however treatment 
with the first-generation vaccine (AN1792) has produced serious adverse events that led to the 
discontinuation of the Phase II trial. AN1792 consists of a synthetic full-length Aβ(1-42) peptide with a 
QS-21 adjuvant. As a result of a T-cell-mediated autoimmune response, 6% of patients have developed 
cerebral inflammation which turned out to be aseptic meningoencephalitis (Gilman et al., 2005).  
Second-generation vaccines were designed using a shorter Aβ(1-6) peptide segment in an attempt to prevent 
nonspecific immune response seen with the full-length vaccine. CAD106, designed by Novartis, was the 
first second-generation vaccine that reached the clinical phases of development (Wiessner et al., 2011). A 
recently completed Phase II clinical trial have shown a Aβ-specific antibody response in 75% of treated 
patients, without causing adverse inflammatory reactions. ACC-001, developed by Janssen, has recently 
completed two phase II trials (NCT01284387 and NCT00479557) with an additional phase II trial still 
ongoing (NCT01227564). However, the pharmaceutical company has abandoned the plans for further 
development of this vaccine. Other vaccines, including tetra-palmitoylated Aβ(1-15) reconstituted in a 
liposome (ACI-24) (Muhs et al., 2007) and MER5101 (Liu et al., 2013) are currently in various stages of 
preclinical development. 
3.4.2 Passive immunization 
This therapy involves passive administration of monoclonal or polyclonal antibodies directed against Aβ. 
It consists of the intravenous administration of anti-Aβ antibodies to the patient. An advantage of this 
strategy compared to active immunization is that the pro-inflammatory T cell-mediated immune reactions 
should not occur. Studies in transgenic animals have shown that passive immunization reduces cerebral 
amyloid load and improves cognition, even when the amyloid plaque numbers are not significantly reduced. 
This could be attributed to the neutralization of soluble amyloid oligomers, which are increasingly 
recognized to play a fundamental role in the pathophysiologic cascade of AD. 
Bapineuzumab and solanezumab are two monoclonal antibodies that have reached advanced stages of 
clinical development (Tayeb, Murray, Price, & Tarazi, 2015). However, in 2012, two Phase III clinical 
trials had failed because of a lack of efficacy in patients with mild-to-moderate AD. Both bapineuzumab 
and solanezumab are humanized monoclonal antibodies against Aβ(1-6) and Aβ(12-28) respectively. In 
case of bapineuzumab, significant reduction in brain amyloid plaques and phosphorylated tau in 
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cerebrospinal fluid was reported. However, the treatment failed to produce significant improvements of 
cognitive function (Stephen Salloway et al., 2014). In a solanezumab trial, infusions of 400 mg of 
solanezumab or placebo were administered once a month for 80 weeks in patients with mild-to-moderate 
AD. The results suggested that solanezumab may improve cognition in mild AD, however statistical 
significance was not achieved in that study (Doody et al., 2014). Currently solanezumab is in Phase III trials 
in patients with AD (NCT01127633 and NCT01900665) and in older individuals who have normal thinking 
and memory function but who may be at risk of developing AD in the future (NCT02008357).  
Another monoclonal antibody, gantenerumab, is being investigated in people at risk of developing presenile 
AD due to genetic mutations. NCT01760005 trial is still recruiting participants and will determine the 
efficacy of both gantenerumab and solanezumab in the prodromal disease stages. In parallel, two additional 
Phase III trials of gantenerumab in patients with mild AD (NCT02051608) and prodromal AD 
(NCT01224106) are ongoing. Gantenerumab is a fully human IgG1 antibody designed to bind with high 
affinity to a conformational epitope on the β-amyloid fibres. Microglia recruitment and ensuing 
phagocytosis will presumably lead to amyloid plaque degradation. Experimental studies in transgenic mice 
support this hypothesis (Bohrmann et al., 2012; Jacobsen et al., 2014; Novakovic et al., 2013). 
Crenezumab (MABT5102A) is a humanized monoclonal antibody which uses IgG4 backbone (Bouter et 
al., 2015). A Phase II clinical trial to assess the safety and efficacy in patients with mild-to-moderate AD 
(NCT01343966) was completed in April 2014, although the results are not yet publicly available. The most 
recent Phase II trial aiming to evaluate the safety and efficacy of crenezumab in asymptomatic carriers of 
E280A autosomal-dominant mutation of PS1 commenced in November 2013 (NCT01998841). 
Other monoclonal antibodies against Aβ developed so far include PF-04360365 (ponezumab) which targets 
the free carboxy-terminal amino acids 33-40 of the Aβ peptide (Miyoshi et al., 2013); MABT5102A, which 
binds to Aβ monomers, oligomers and fibrils with equally high affinity (Adolfsson et al., 2012); 
GSK933776A, which is similar to bapineuzumab in that it binds to the N-terminal Aβ(1-5) (Novakovic et 
al., 2013). In addition, other passive immunotherapies mostly in Phase I clinical development include NI-
101, SAR-228810 and BAN-2401 (Ghezzi, Scarpini, & Galimberti, 2013).  
Intravenous immunoglobulin product Gammagard is a preparation of antibodies from human plasma. Its 
safety for human use had been previously demonstrated in certain autoimmune conditions. Gammagard 
effects were evaluated in a small number of AD patients (NCT00818662). It is believed that this mixture 
contains a small fraction of polyclonal antibodies against the Aβ peptide. In addition, this preparation may 
possess immunomodulatory properties that could potentially enhance microglial phagocytosis (Dodel et al., 
2013; Relkin et al., 2009). 
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3.5 Strategies focused on tau proteins  
Tau proteins are highly soluble and abundant in the neurons where they play a critical role in microtubule 
stabilization, particularly in axons. Tau hyperphosphorylation leads to the formation of insoluble paired 
helical filaments (PHF) which form neurofibrillary tangles (see Fig. 1 on page 17). The loss of microtubule-
binding capacity provokes cytoskeleton destabilization, which eventually causes neurodegeneration and 
neuronal death (Cowan & Mudher, 2013). As an alternative to amyloidocentric approaches, Tau-centered 
treatments aim to inhibit the phosphorylation and/or aggregation of tau protein. In addition, microtubule-
stabilizing drugs could be used as a disease-modifying strategy in AD. In recent years, immunomodulation 
was suggested as a viable option for promoting effective clearance of tau aggregates (West & Bhugra, 
2015). 
3.5.1 Inhibitors of tau hyperphosphorylation 
All tau proteins are a product of alternative splicing of a microtubule-associated protein tau (MAPT) gene. 
Phosphorylation is the primary mechanism which regulates tau binding to microtubules. Under 
physiological conditions the protein remains soluble, however in AD, pathological hyperphosphorylation 
of tau compromises its normal functions. Hyperphosphorylation occurs as a result of an imbalance between 
the catalytic activity of kinases and phosphatases. Increased expression of active forms of various kinases 
in the areas proximal to neurofibrillary tangles has been described in AD, including CDK5, GSK3β, Fyn, 
stress-activated protein kinases JNK and p38, and mitogen-activated protein kinases ERK1 and ERK2. 
Some or all of these kinases contribute to the perpetuation of the phosphorylation of tau in neurofibrillary 
tangles (A. V. de la Torre et al., 2012; Folch et al., 2012, 2015; Iqbal, Gong, & Liu, 2014; Kimura, Ishiguro, 
& Hisanaga, 2014).  As a result, significant research efforts have been devoted to the development of kinase 
inhibitors as a possible treatment strategy for AD. For example SP600125, a widely used pan-JNK inhibitor, 
exerts beneficial effects on cognition and reduces neurodegeneration in an APP/PS1 transgenic mouse 
model of AD (Zhou et al., 2015). It has been proposed that specific inhibition of JNK3 could be sufficient 
to bring similar benefits as seen with SP600125 in rodent models. Human data in AD patients indicate a 
positive correlation between the levels of JNK3 and Aβ (1-42) in the brain. Furthermore, JNK3 upregulation 
was detected in the CSF and was associated with memory loss. Thus, JNK3 inhibition remains a promising 
target for future therapies (Gourmaud et al., 2015). 
CDK5 belongs to the family of serine/threonine cyclin-dependent kinases and is responsible for a number 
of physiological functions within the CNS, including neurite outgrowth and the regulation of axonal 
development. CDK5 catalytic activity is dependent on its direct association with p35, key regulator of 
CDK5 signaling. This cofactor is cleaved by a non-lysosomal protease calpain in a calcium-dependent 
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manner. Conversion of p35 to p25 results in prolonged activation and mislocalization of CDK5. Due to the 
increases in intracellular calcium levels observed in the brains of AD patients, pathological activation of 
CDK5 occurs, resulting in hyperphosphorylation of tau and neuronal cell death (Camins, Verdaguer, Folch, 
Canudas, & Pallàs, 2006; Kimura et al., 2014). CDK5 inhibition may thus also be potentially considered as 
a possible drug target. Currently existing CDK5 inhibitors roscovitine and flavopiridol have demonstrated 
neuroprotective properties in in vitro and in vivo models of excitotoxicity, ischemia and neurodegeneration 
(Jorda et al., 2003). 
GSK3β inhibitors are arguably in the most advanced stages of clinical development for AD. Among the 
various drugs that are currently being studied, tideglusib, an irreversible inhibitor of GSK3β, has recently 
completed Phase II trials (NCT01350362). Tideglusib administration for a period of 26 weeks to patients 
with mild-to-moderate AD did not show clinical efficacy, and the compound has since been discontinued 
for this indication (Lovestone et al., 2015). Another study (NCT00948259) evaluated the safety and 
tolerability of a 20-week administration of NP031112 compared with placebo in patients with AD. No data 
has been reported for this study. 
Phosphatase activation has also been considered as a possible drug target. Currently, there is only one 
protein phosphatase 2 (PP2A) agonist in development. Sodium selenite (VEL015) is undergoing Phase II 
trials in Australia (ACTRN12611001200976). Experimental studies have shown that sodium selenate 
reduces tau phosphorylation, both in cell culture and in mouse models of the disease. VEL015 
administration to rodents have resulted in significant cognitive improvements and substantial reduction of 
neurodegenerative phenotype (Corcoran et al., 2010; van Eersel et al., 2010). 
3.5.2 Inhibitors of tau aggregation  
Hyperphosphorylated tau aggregates contribute to neurotoxicity observed in AD brain. Methylene blue dye 
(methylthioninium chloride - MTC) derivatives have shown some promise in inhibiting the formation of 
tau aggregates. Methylene blue disrupts the aggregation of tau, has the ability to inhibit amyloid 
aggregation, improves the efficiency of mitochondrial electron transport chain, reduces oxidative stress, 
prevents mitochondrial damage and is also a modulator of autophagy (Baddeley et al., 2015; Hochgräfe et 
al., 2015). The first-generation formulation containing methylene blue (Rember) appeared to stabilize AD 
progression in a clinical trial which lasted 50 weeks (Wischik, Harrington, & Storey, 2014). These results 
motivated researchers to develop a next-generation version of methylene blue, TRx 0237. This compound 
is a purified derivative of methylene blue which not only inhibits tau protein aggregation but also dissolves 
brain aggregates of tau. Several clinical trials are currently underway (NCT01626391, NCT01689233, 
NCT01689246, NCT01626378) to evaluate the potential efficacy of this drug in AD. 
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3.5.3 Microtubule stabilizers 
Microtubule stabilization may potentially achieve a similar end-result as that seen with the inhibitors of tau 
hyperphosphorylation and aggregation. Paclitaxel is a microtubule-stabilizing drug currently in use in the 
oncology field. Unfortunately, this compound is incapable of crossing the BBB and its use is associated 
with serious adverse events, which limits its utility in AD (Patel, Gajbhiye, & Jain, 2015; Shemesh & Spira, 
2011). In addition to paclitaxel, other microtubule-stabilizing compounds such as TPI-287 have been 
considered as a possible AD therapy. TPI-287 is a derivative of taxane, also used in cancer treatment. TPI 
287 stabilizes the microtubules by binding to tubulin. NCT01966666 clinical trial will evaluate TPI-287 
safety, pharmacokinetic properties and tolerability by intravenous infusion in mild-to-moderate AD. 
Epothilone D is a microtubule-stabilizing compound which improved axonal transport, reduced axonal 
dystrophy, decreased tau neuropathology, and reduced hippocampal neuron loss, however drug 
development for AD was discontinued in 2013 after a failed clinical trial (Zhang et al., 2012). 
With respect to tau, additional studies are necessary in order to better understand the exact molecular 
mechanisms involved in tau neurotoxicity. Recent studies comparing the neurotoxic profiles of various 
forms of tau suggest that a soluble form is likely the most toxic (Cowan & Mudher, 2013). This has been 
corroborated by a recent report specifically identifying oligomeric tau as toxic (Kumar et al., 2014). 
Therefore, future therapeutic strategies should be focused on targeting soluble forms of tau. 
3.5.4 Anti-tau immunotherapy 
Just as with the immunotherapies targeting Aβ, both passive and active immunization approaches against 
tau have been considered. In fact, it was demonstrated that reductions in tau aggregate formation and 
improved clearance of tau oligomers and insoluble aggregates could all be achieved with either active or 
passive immunotherapies (Anand & Sabbagh, 2015). In rodents, treatment with monoclonal antibodies 
directed against hyperphosphorylated tau has led to improvements in cognition and was not associated with 
significant adverse effects (Yanamandra et al., 2013). 
In 2013 Axon Neuroscience began a Phase I trial to evaluate the safety and tolerability of AADvac-1, an 
active immunotherapy which consists of a synthetic peptide derived from the tau sequence coupled to 
keyhole limpet hemocyanin, the precise molecular nature of the antigen has not been disclosed 
(NCT01850238 and NCT02031198). AADvac-1 uses aluminum hydroxide as an adjuvant (Kontsekova, 
Zilka, Kovacech, Novak, & Novak, 2014). At the 2014 Alzheimer's Association International Conference 
(AAIC) in Copenhagen, good preclinical safety profile was reported for the treatment period of up to 6 
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months in rats, rabbits, and dogs. These early results are encouraging and it remains to be seen whether 
AADvac-1 will demonstrate acceptable safety and efficacy in human patients. 
3.6 Dendritic Hypothesis (Aβ-PrPC–mGluR5–Fyn signaling) 
Dendritic hypothesis is described in some detail on page 24. Some data suggest that soluble Aβ oligomers 
are the principal neurotoxic species responsible for dendritic pathology. Aβ oligomers may cause aberrant 
N-methyl-D-aspartate receptor (NMDAR) activation post-synaptically by forming complexes with the cell-
surface prion protein (PrPC). PrPC is enriched at the neuronal post-synaptic density, where it interacts with 
Fyn tyrosine kinase-metabotropic glutamate receptor 5 complex (Fyn-mGluR5). Fyn activation occurs 
when Aβ is bound to PrPC-Fyn-mGluR5 complex. Activated in this manner, Fyn can cause tyrosine 
phosphorylation of the NR2B subunit of this NMDAR. This results in an initial increase and then a loss of 
cell-surface NMDARs (Um et al., 2013). Fyn overexpression accelerates synapse loss and the onset of 
cognitive impairment in the J9 (APPswe/Ind) transgenic AD mouse model, while its inhibition produces an 
opposite effect (Um et al., 2012). In addition, as mentioned earlier (page 40), Fyn can also contribute to tau 
hyperphosphorylation. Previous studies had reported elevated levels of Fyn in AD brain. Furthermore, Fyn 
was shown to phosphorylate tau at Tyr18 residue (Bhaskar, Yen, & Lee, 2005). Thus, Fyn appears to be a 
viable target in the treatment of AD pathology. Saracatinib (AZD0530) and masitinib (AB1010) are Fyn 
kinase inhibitors currently in Phase II and III clinical trials for mild-to-moderate AD (NCT01864655, 
NCT02167256, NCT00976118 and NCT01872598) (Folch et al., 2015). Both compounds are capable of 
blocking Fyn in a nanomolar range.  
In a NCT00976118 clinical trial, oral masitinib was administered for a period of 24 weeks, concomitantly 
with one of the AChEIs (donepezil, rivastigmine, or galantamine) and/or memantine. In that study a 
significant improvement in the ADAS-Cog test response was reported. These results are encouraging, 
however the very small patient pool (n=26) on memantine in this Phase II trial is clearly not sufficient to 
draw conclusions on the potential efficacy of this compound (Piette et al., 2011). MOA of masitinib in AD 
is twofold. Apart from blocking Fyn, masitinib is also a stem cell factor (SCF) receptor (c-KIT) inhibitor. 
By inhibiting SCF/c-Kit signaling on mast cells (MCs), this compound may prevent neuroinflammation by 
blocking the activated MCs-microglia interactions (Folch et al., 2015).  
3.7 5-HT6 receptors in Alzheimer’s disease 
5-HT6 receptors are expressed in areas of the CNS involved in learning and memory. Their inhibition was 
shown to promote acetylcholine release (Riemer et al., 2003). In AD, 5-HT6 antagonism may lead to the 
restoration of acetylcholine levels (Ramirez, Lai, Tordera, & Francis, 2014). This hypothesis is supported 
by evidence that the 5-HT6 receptor antisense oligonucleotides improve spatial learning and memory in the 
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Morris water maze test in normal rats (Woolley, Bentley, Sleight, Marsden, & Fone, 2001). 5-HT6 
inhibitors may be useful in combination therapy, together with AChEIs. For example, Lu-AE-58054 (SGS-
518) and PF-05212365 (SAM-531) are being considered as possible treatments for mild-to-moderate AD. 
Other compounds that are in various stages of clinical research are SUVN-502, AVN-322 and PRX-07034 
(Ramírez, 2013). 
3.8 Changing the concept: AD as a metabolic disorder 
Clinical studies suggest that diabetes is a major risk factor that contributes to AD pathology. Results from 
published research indicate that there is a close link between insulin-deficient diabetes and cerebral 
amyloidosis (De Felice, 2013). Peripheral and central insulin signaling impairments are likely present in 
both diseases. As a result, “type-3 diabetes” hypothesis of AD was developed (page 24), which attempts to 
bridge the observed metabolic phenotypes present in diabetes and AD into a coherent framework. Insulin 
hormone is at a centerpiece of this hypothesis (S. M. de la Monte & Wands, 2008).  
Observations made in the “Hisayama Study” indicate that altered expression of genes related to diabetes 
mellitus in AD brains may be a result of AD pathology, and suggest that peripheral insulin resistance, 
metabolic syndrome and/or full-blown diabetes may lead to worsening of cognitive symptoms. Impaired 
central insulin signaling in the hippocampal circuits, a key region involved in learning and memory, is 
likely present in AD (Hokama et al., 2014). Glucose toxicity, insulin resistance, oxidative stress, elevated 
levels of advanced glycation end products and cytokine-mediated neuroinflammation are among the 
proposed mechanisms by which diabetes could increase the risk of AD development. In a recent study, 
Clarke and colleagues demonstrated that intracerebroventricular infusion of soluble Aβ oligomers initiates 
neuroinflammatory cascades which eventually cause disturbances in peripheral glucose homeostasis 
(Clarke et al., 2015). Tumor necrosis factor α (TNFα) quite possibly plays an important role in this process 
(Lourenco et al., 2013).  
As molecular mechanisms causing AD and T2DM pathologies are possibly related, it is logical to assume 
that drugs used in T2DM treatment may have a neuroprotective effect in AD. Thiazolidinediones (TZDs) 
are an example of anti-diabetic compounds whose possible role in AD was investigated. TZDs are agonists 
of peroxisome proliferator-activated receptor  (PPAR-), which act by promoting PPAR- 
heterodimerization with the retinoid X receptor (RXR). PPAR-/RXR heterodimer is a transcription factor 
which regulates expression of genes involved in lipid and glucose metabolism. TZDs improve insulin 
sensitivity and reduce cytokine-dependent inflammation. Rosiglitazone and pioglitazone are used as anti-
diabetic drugs which regulate glucose homeostasis by increasing insulin sensitivity, reducing blood glucose 
levels and improving lipid metabolism. Both compounds have also been studied as potential therapeutics 
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for AD treatment, with reported improvements in mitochondrial oxidative metabolism (Blalock et al., 2010; 
Gold et al., 2010; Risner et al., 2006). In animal models, pioglitazone modified various indices of brain 
aging but did not slow down the cognitive decline (Blalock et al., 2010).  Rosiglitazone and pioglitazone 
also induce the expression of peroxisome proliferator-activated receptor- co-activator 1 alpha (PGC-1α), 
a molecule that plays multiple roles in mitochondrial biogenesis, energy metabolism and mitochondrial 
antioxidants expression. Previous studies have demonstrated that in human brain tissues, the expression of 
PGC-1α decreases with progression of AD dementia (Qin et al., 2009). Thus, PGC-1α upregulation may 
improve the mitochondrial energy metabolism and AD pathology (Katsouri, Parr, Bogdanovic, Willem, & 
Sastre, 2011). 
Pioglitazone treatment improved memory and cognition in patients with mild-to-moderate AD in a small 
clinical trial (Sato et al., 2011). A much larger clinical trial demonstrated improvements in memory 
retention and attention with rosiglitazone treatment (6 months) in patients who did not possess an ApoE4 
allele (Risner et al., 2006). However, another major phase III trial using rosiglitazone failed to show efficacy 
in AD (NCT00550420) (Gold et al., 2010). It is important to note that in these trials rosiglitazone was 
administered alone at dosages that were much lower than those needed to exert a beneficial effect on AD 
pathophysiology in rodent models of the disease. NCT00348140 is a recently completed clinical trial in 
which rosiglitazone was administered in combination with AChEIs in patients with mild-to-moderate AD. 
No results have yet been reported. 
Intranasal insulin was also considered as a treatment option for AD. This particular route of administration 
is attractive as it bypasses the BBB. This is very significant because insulin transport to the brain from the 
periphery is dependent on active transport mechanisms which may become disrupted in AD. In addition, 
the probability of possible adverse events in peripheral tissues is minimized. In theory, insulin delivery 
directly to the brain will activate cerebral insulin signaling leading to improvements in memory processing 
and will result in neuroprotection (Claxton et al., 2015; Freiherr et al., 2013; Hölscher, 2014). A currently 
ongoing clinical trial NCT01767909 is evaluating long-term (12 months) efficacy of intranasal insulin 
(Humulin RU-100) in mild AD.  
Other pancreatic hormones such as amylin may also play a role in AD. Adler and colleagues reported that 
patients with AD have reduced concentrations of plasma amylin. In transgenic animal models of AD, 
amylin and pramlintide (amylin analog) decreased brain Aβ levels and improved cognition. Interestingly, 
amylin also inhibited β-secretase enzyme, while pramlintide did not (Adler et al., 2014; Qiu & Zhu, 2014). 
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Table 2. A list of drug candidates which were considered as a possible AD treatment in humans 
Section MOA Compound Clinicaltrials.gov Trial ID #  (if mentioned)
E2609 NCT01600859
MK-8931 NCT01739348
LY2886721 NCT01807026; NCT01561430
LY450139 (Semagacestat) NCT00762411; NCT01035138; NCT00762411
Avagacestat NCT00810147; NCT00890890; NCT00810147; NCT01079819
NIC5-15 (pinitol) NCT00470418
R-flurbiprofen (Tarenflurbil)
Ibuprofen
CHF-5074
GABAergic; binds soluble Aβ 3-APS (Alzhemed, tramiprosate)
Possible immunomodulator Colostrinin
Aβ aggregation blocker? ELND005 (Scyllo-inositol)
Clioquinol
PBT2
PF-0449470052
TTP4000 NCT01548430
AN1792
CAD106
ACC-001 NCT01284387; NCT00479557; NCT01227564
ACI-24
MER5101
Bapineuzumab
Solanezumab NCT01127633; NCT01900665; NCT02008357; NCT01760005
Gantenerumab NCT01760005; NCT02051608; NCT01224106
MABT5102A (Crenezumab) NCT01343966; NCT01998841
PF-04360365 (Ponezumab)
GSK933776A
NI-101
SAR-228810
BAN-2401
Intravenuos IgG product Gammagard NCT00818662
Roscovitine
Flavopiridol
Tideglusib NCT01350362
NP031112 NCT00948259
PP2A agonism VEL015 (Sodium selenate) ACTRN12611001200976 *** Australian clinical trial
Rember
TRx 0237 NCT01626391; NCT01689233; NCT01689246; NCT01626378
Paclitaxel
TPI-287 NCT01966666
Epothilone D
3.5.4 Active anti-Tau vaccine AADvac-1 NCT01850238; NCT02031198
Fyn inhibition AZD0530 (Saracatinib) NCT01864655; NCT02167256
Fyn + c-KIT inhibition AB1010 (Masitinib) NCT00976118; NCT01872598
Lu-AE-58054 (SGS-518)
PF-05212365 (SAM-531)
SUVN-502
AVN-322
PRX-07034 
3.8 Rosiglitazone NCT00550420; NCT00348140
Pioglitazone 
Intranasal insulin Humulin RU-100 NCT01767909
PPAR-g + PGC-1α agonism
3.3.1 β-secretase inhibition
γ-secretase inhibition and 
modulation
NSAID; possible γ-secretase 
inhibition
3.3.2
antifungal; metal chelator?
3.3.3
RAGE inhibition/modulation3.3.4
Active anti-Aβ vaccine3.4.1
5-HT6 receptor inhibition3.7
anti-Aβ antibodies / passive 
immunization3.4.2
CDK5 inhibition
GSK3β inhibition
3.5.1
Tau aggregation inhibition3.5.2
Microtubule stabilization3.5.3
3.6
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3.9 Summary 
Data described in this section offer ample evidence that AD is a highly complex disease. AChEIs and 
memantine are the only drugs currently approved for this condition. Nevertheless, the field of AD research 
does not stand still and a multitude of treatment options are considered. Unfortunately, based on historical 
evidence, the vast majority of pharmaceuticals described here are likely to fail. Hopefully, a targeted therapy 
capable of reversing the course of AD will be developed some time in the future. In the meantime, both the 
scientific community and the pharmaceutical industry are likely to remain very busy identifying key targets 
responsible for this devastating disease. In our opinion, a truly successful therapy will need to take into 
account the convergence of multiple factors which form an integral part of the disease process. A 
combination of early detection in the prodromal stages of AD, the role of metabolism and the possibility of 
combined pharmacotherapies should be considered (Fig. 3). 
DISCLAIMER: Large portions of text presented in Sections 3.3-3.8 were recently accepted for publication 
to Neural Plasticity Journal (Hindawi Publishing Corporation) (supplementary Publication on page 111).
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Figure 3. Future strategies in the treatment of late-onset and sporadic forms of AD could be centered on 
three main points: avoidance of habits and lifestyle leading to obesity and diabetes; early detection of AD 
biomarkers or structural alterations in pre-symptomatic individuals; and combined therapies in early phases 
of cognitive loss. *Accepted, Neural Plasticity (Hindawi Publishing Corporation)
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OBJECTIVES 
Overall objectives of the present doctoral thesis are to determine the changes which occur at the molecular 
level as a result of a high-fat diet administration in 3- and 6-month old APPswe/PS1dE9 mice, a transgenic 
model of familial Alzheimer disease. More specifically: 
1. Characterization of the peripheral and central metabolic phenotypes at 3 and 6 months of age in 
APPswe/PS1dE9 versus the wild-type mice on a standard chow in order to: 
A) Determine if transgenic status has an effect on peripheral carbohydrate metabolism 
B) Determine if hippocampal insulin signaling is altered in mice predisposed to Alzheimer 
disease development 
C) Identify molecular pathways which are altered in early stages of AD-like pathology, 
prior to amyloid plaque development and memory loss in hippocampal circuits 
 
2. Characterization of the peripheral and central metabolic phenotypes in 6-month-old 
APPswe/PS1dE9 versus the wild-type mice on a high-fat diet. In addition to the 1A and 1B 
described above, the following objectives are considered: 
A) Determine if high-fat diet treatment differentially affects wild-type and transgenic mice 
B) Determine if chronic hypercaloric diet administration affects memory 
C) Determine if high-fat diet accelerates AD-like pathology 
D) Determine if hypercaloric diet affects hippocampal signaling molecules traditionally 
associated with AD
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Publication 1 
 
EARLY ALTERATIONS IN ENERGY METABOLISM IN THE HIPPOCAMPUS OF 
APPSWE/PS1DE9 MOUSE MODEL OF ALZHEIMER'S DISEASE 
Ignacio Pedrós, Dmitry Petrov*, Michael Allgaier, Francesc Sureda, Emma Barroso, Carlos Beas-Zarate, 
Carme Auladell, Mercè Pallàs, Manuel Vázquez-Carrera, Gemma Casadesús, Jaume Folch, Antoni Camins 
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2014), 1842(9): 1556-1566 
 
Summary 
APP/PS1 transgene causes CNS-directed overexpression of both a chimeric mouse/human APP and the 
exon 9-deleted variant of PS1. As a result, elevated levels of “humanized” Aβ protein are secreted in the 
brain of transgenic mice. In this paper, we determine peripheral metabolic status (by IPGTT and ITT) and 
the changes which occur in the hippocampus in 3- and 6-month-old animals. NOR test indicates that 
memory is not significantly affected in younger mice. At this age, neither diffuse nor fibrillar cerebral 
plaque deposits were detectable and no significant differences in glucose and insulin tolerance were 
observed. However, a significant increase in the insoluble Aβ (1-42) was detected in the cortical extracts 
of 3-month-old APP/PS1 mice. Furthermore, a number of genes related to memory (FOS, ARC) and insulin 
signaling (INS-R) were downregulated in the hippocampus of young transgenic animals, compared to wild-
type. In addition, tau hyperphosphorylation, disruptions in mitochondrial OXPHOS and reduced expression 
of molecules responsible for mitochondrial biogenesis (PGC-1α, NRF1 and NRF2) were also detected. By 
the age of 6 months, transgenic mice developed readily visible senile plaques, pronounced memory loss, 
impaired glucose and insulin tolerance, continued disruptions in OXPHOS complexes and mitochondrial 
biogenesis signaling, as well as significantly increased levels of insoluble Aβ(1-40) and Aβ(1-42). These 
data indicate that hippocampal insulin signaling and mitochondrial metabolism deficiencies occur prior to 
the appearance of senile plaques, memory loss and peripheral carbohydrate metabolism alterations in an 
APP/PS1 mouse model of FAD. 
 
  * Equally contributing first author  
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Publication 2 
 
HIGH-FAT DIET-INDUCED DEREGULATION OF HIPPOCAMPAL INSULIN 
SIGNALING AND MITOCHONDRIAL HOMEOSTASIS DEFICIENCES 
CONTRIBUTE TO ALZHEIMER DISEASE PATHOLOGY IN RODENTS 
Dmitry Petrov, Ignacio Pedrós, Gonzalo Artiach, Francesc Sureda, Emma Barroso, Mercè Pallàs, Gemma 
Casadesús, Carlos Beas-Zarate, Eva Carro, Isidro Ferrer, Manuel Vázquez-Carrera, Jaume Folch, Antoni 
Camins 
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2015), 1852(9): 1687-1699 
 
Summary 
Continuous HFD administration starting at the time of weaning was previously demonstrated to cause 
relational memory loss in a subpopulation of wild-type mice by 5 months of age. In order to determine if 
molecular mechanisms leading to memory defects are significantly different between the HFD-treated 
control animals and mice predisposed to AD development, we have administered HFD to wild-type and 
APP/PS1 mice until they reached 6 months of age. HFD treatment resulted in significant body-weight 
increase, increases in plasma insulin and triglyceride levels, significantly impaired glucose and insulin 
tolerance and memory loss in both groups. HFD-exposed transgenic mice demonstrated significant 
worsening of peripheral metabolic parameters when compared to HFD-fed control animals. Both the 
cerebral senile plaque size and quantity remained unaffected by HFD treatment. On a molecular level, HFD 
produced changes in hippocampal expression of some genes related to insulin signaling (INS1, INS-R, 
IGF1-R) in transgenic mice only, while some other molecules, notably IGF1 and pIRS2, exhibited different 
response in treated APP/PS1 vs. wild-type. Furthermore, OXPHOS deficiencies were detected in treated 
wild-type animals, as well as in both untreated and treated APP/PS1 mice. Interestingly, we have observed 
increases in Tau phosphorylation and elevated expression of associated kinases in HFD-treated wild-type 
mice. Taken together, our data suggest that hypercaloric diet is capable of inducing changes in the 
hippocampal signaling networks, some of which parallel those observed in mice predisposed to AD. 
Conversely, transgenic mice on a normal diet demonstrate some of the deficiencies which only appear in 
response to HFD in wild-type animals. AD-like pathology appears to amplify HFD-induced metabolic 
perturbations. 
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1. OVERVIEW 
As mentioned in the introductory sections, AD is a complex pathology which is highly resistant to 
pharmaceutical interventions. Apart from the genetic component and old age, seven primary preventable 
environmental risk factors contributing to AD have been identified: diabetes mellitus, midlife hypertension, 
midlife obesity, depression, physical inactivity, smoking and cognitive inactivity (Barnes & Yaffe, 2011; 
Norton, Matthews, Barnes, Yaffe, & Brayne, 2014). Thus, it is becoming increasingly evident that most of 
the prognostic preventable AD risk factors may also be linked to obesity and resulting comorbidities, 
including metabolic syndrome and diabetes. Even though the epidemiological data suggest an existing 
relationship between AD and energy metabolism, molecular mechanisms behind this relationship are poorly 
understood. In the work described in this thesis we wanted to address the role of metabolism in AD. While 
it is true that an APP/PS1 mouse model in which the experiments were undertaken is a rodent model of 
FAD, and FAD represents only 2% of all diagnosed cases of AD, we believe that this experimental approach 
is nevertheless capable of identifying certain molecular aspects of the disease which could be useful for 
understanding the bigger picture.  
In the planning stages, as a first step, we wanted to establish whether insulin signaling is affected in our 
model at the relatively early disease stages. The reason for choosing younger animals is that at the age of 3 
months, the typical pathological hallmarks of the disease (senile plaques and neurofibrillary tangles) are 
not yet present in the brains of these mice. By the age of 6 months, the plaques are already evident and 
hippocampal-dependent memory deficits are observed. However, even at the age of 6 months, the disease 
has presumably not yet taken an irreversible aspect. That is to say that the phenotype is not severe enough 
to affect gross cerebral morphology and that the changes observed at this age are likely to be a direct result 
of elevated levels of Aβ peptide. Having determined that hippocampal insulin signaling is indeed disturbed 
in transgenic animals, and that by the age of 6 months APP/PS1 mice develop impaired glucose and insulin 
tolerance (Publication 1: (Pedrós et al., 2014)) we proceeded with the second major part of this work which 
is reflected in the title of the current thesis – “The role of high-fat diet in an APP/PS1 model of familial 
Alzheimer disease”. 
Our initial approach was to analyze the changes which occur in response to a HFD treatment in 3- and 6-
month-old wild-type and transgenic mice. Unfortunately, the first data which we have collected in 3-month-
old animals were rather ambiguous and demonstrated a very significant biological variability. Due to these 
limitations, a decision was made to focus on 6-month-old animals only. As described in Publication 2 
(Petrov et al., 2015), continuous HFD treatment is sufficient to cause hippocampus-dependent memory 
deficits in wild-type mice. The scientific rationale for studying the phenotypes of mice in which cognition 
was likely to be altered a priori, was to determine the biological relationship between the HFD- and AD-
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related memory loss. In addition, we wanted to see if AD-like pathology could lead to the exacerbation of 
HFD-caused metabolic and CNS phenotypes. The next sections of the discussion are organized in the 
following manner:    
 Changes which occur in the periphery 
o 3-month-old animals on normal chow 
o 6-month-old mice on control and HF diets 
 
 CNS phenotype 
o 3-month-old animals on normal chow 
o 6-month-old mice on control and HF diets 
 
DISCLAIMER: In order to avoid simply copying large portions of the Discussion sections of the papers 
presented in the Results section, the analysis described here concerns some of the issues that were not fully 
addressed in Publications 1 and 2. In addition, I will be focusing on the entire pathways as opposed to the 
role of individual molecules, as the role of each one was described in some detail in the presented research 
papers.
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2. PERIPHERAL PHENOTYPE 
2.1 3 months of age – normal diet 
Fasting levels of serum insulin remained unchanged between the wild-type and the transgenic animals. We 
did observe a slight but not a significant increase in glucose levels as a result of intraperitoneal glucose 
administration in the IPGTT in APP/PS1 mice. The data strongly suggest that the peripheral metabolic 
phenotype is unaffected at this age. 
2.2 6 months of age 
By the time the mice are 6 months old, peripheral metabolism differences start to become apparent. Even 
on a control diet, APP/PS1 mice show impairments in the glucose and insulin tolerance. HFD results in 
diet-induced obesity, with differences in body weight starting to become evident at around 2 months of age. 
At the end of the experiment, an approximately 50% weight gain is recorded. The classical features of the 
metabolic syndrome are present in both the wild-type and the transgenic animals at this age. We detected 
peripheral hyperinsulinemia, dyslipidemia, significantly impaired glucose and insulin tolerance and 
obesity. The most important finding in our work is that all of these metabolic parameters were significantly 
worse in transgenic mice. In fact, HFD alone was not sufficient to raise basal fasting blood glucose levels 
after an overnight fast in wild-type mice, but in APP/PS1 animals hypercaloric diet treatment produced an 
over 50% increase in basal glucose. It is quite striking that increases in triglyceride (TG) levels and the 
extent of impairments detected in IPGTT and ITT demonstrated an almost additive effect as a result of a 
HFD and the transgenic status. When looking at the graphs of TG, IPGTT and ITT (Fig. 1; (Petrov et al., 
2015), one can see that the wild-type mice on a HFD present a nearly identical profile as that seen with 
APP/PS1 mice on a control diet. When transgenic animals were fed a hypercaloric diet, all three of these 
parameters moved to a nearly diabetic range. Thus, it appears that elevated cerebral secretion of Aβ peptide 
is sufficient to produce changes in peripheral carbohydrate metabolism which are comparable to those 
observed with chronic HFD administration. Crucially, in transgenic control animals the body weight is 
similar to wild-type control mice. Therefore, obesity by itself can-not explain this peripheral metabolic 
phenotype. The exact mechanisms responsible for this observation are unclear. I can only speculate that 
excess amyloid, while initially produced in the brain, eventually enters into the peripheral circulation (see 
introductory section 3.3.4). Once in the periphery, it might be subject to degradation by IDE or other insulin-
degrading enzymes. Assuming that under normal conditions endogenous peripheral insulin is indeed 
degraded by IDE in a physiologically relevant manner (which is controversial (Authier, Posner, & 
Bergeron, 1996; Deprez-Poulain et al., 2015; Farris et al., 2004)), then the presence of beta amyloid may 
result in a competitive inhibition of the enzyme. This could then theoretically lead to increased plasma 
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insulin and the development of peripheral insulin resistance which would be reflected by impaired glucose 
and insulin tolerance. It is important to note, that our results do not show significant increases in serum 
insulin levels on a control diet (Fig. 2 (Pedrós et al., 2014); Fig. 1 (Petrov et al., 2015)). However, the 
measurements were taken after a 5-hour morning fast, which may be enough time for any possible 
differences to disappear. The reason why we do see clear differences in insulin levels in response to HFD 
treatment, is a direct result of obesity, which would cause chronically elevated insulin levels even in fasted 
mice. In any case, these data are very interesting and warrant additional investigation in further detail.
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3. CNS PHENOTYPE 
3.1 3 months of age – normal diet 
Hippocampus-dependent memory loss is not present at this age. Therefore, all of the observed changes can 
be considered as events which occur in the prodromal stages of AD.   
3.1.1 Amyloidogenesis and Tau 
Elevated levels of APP mRNA were present in the hippocampi of transgenic mice. We had also detected 
significant amounts of insoluble Aβ (1-42) in the cortical homogenates of 3-month-old APP/PS1 animals. 
At this age, no visible senile plaques nor neurofibrillary tangles are detectable by microscopy. These data 
suggest that at this age, the endogenous defense mechanisms which protect against amyloid aggregation 
are capable of coping with the excess of amyloid peptides.  
With regards to tau, we have observed tau hyperphosphorylation at multiple residues (S199; T205; S404) 
in transgenic mice, indicating that tau pathology may begin to manifest itself as early as 3 months of age. 
We did not detect elevated expression in some of the kinases which are known to lead to tau 
hyperphosphorylation (see section 3.5.1 of the introduction). Protein levels of activated forms of MAPK 
and GSK3β remained unchanged. We did detect a slight but significant increase in CDK5, however this 
increase was accompanied by elevated expression of p35, suggesting that this kinase may not necessarily 
be involved (section 3.5.1 as well). Further studies may be necessary to identify the kinase/s responsible 
for tau hyperphosphorylation at such an early age. 
3.1.2 Mitochondrial metabolism and biogenesis 
Hippocampal mitochondrial metabolism is clearly impaired in 3 month old transgenic mice as evidenced 
by significant reductions in OXPHOS complexes I, II, II and IV. Furthermore, we detected reductions in 
molecules involved in mitochondrial biogenesis including PGC-1α, NRF1 and NRF2. Taken together, our 
results do not contradict neither the “amyloid cascade” (due to the presence of insoluble amyloid) nor the 
“mitochondrial cascade” hypotheses (see pages 16 and 20). 
3.1.3 Hippocampal insulin signaling  
We did not detect major changes in the insulin- INS-R -IRS axis in 3-month-old APP/PS1 mice. However, 
small but significant differences were observed in the mRNA levels of the INS-R and IRS2, suggesting that 
at this age the very early signs of hippocampal insulin signaling defects may just be starting to appear. In 
addition, we observed a significant reduction in genes related to memory, ARC and FOS, both of which are 
known to be regulated by insulin signaling (Guillod-Maximin, Lorsignol, Alquier, & Pénicaud, 2004; 
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Kremerskothen, Wendholt, Teber, & Barnekow, 2002). Please note that in the Fig. 3 of the Publication 1, 
the statistical significance marking was erroneously transposed to IRS1, instead of IRS2. The data presented 
in the discussion of the above mentioned paper correctly identifies IRS2 as the molecule mRNA levels of 
which were significantly reduced. 
3.1.4 Synaptic proteins 
According to the “synaptic dysfunction” hypothesis (page 24), synaptic loss may occur as a result of Aβ 
oligomer accumulation, at a stage prior to the senile plaque formation. As we have detected elevated levels 
of Aβ in the hippocampi of 3-month-old APP/PS1 mice, we have measured the levels of SYP and PSD-95, 
both of which are the biomarkers of the healthy synapses. Protein expression levels of neither of the 
molecules were affected by transgenic status.  
3.1.5. Summary 
On the whole, the data described here is indicative of the presence of the early stages of amyloidogenesis, 
tau dysfunction, mitochondrial metabolism and biogenesis defects and the beginnings of hippocampal 
insulin signaling perturbations in the hippocampi of 3 month-old transgenic mice. Once again, all these 
changes occur in the prodromal disease stages, prior to measurable cognitive deficits. 
3.2 6 months of age 
As mentioned in the overview, we had reason to suspect that hippocampal-dependent memory loss will be 
present in the HFD-treated wild-type mice. That did turn out to be the case. At the age of 6 months, cognition 
was affected in HFD-treated wild-type, as well as in control and HFD-treated APP/PS1 animals. 
3.2.1 Amyloidogenesis and Tau 
Cortical Aβ peptide levels were negligible in wild-type mice. In transgenic animals only the insoluble Aβ 
(1-42) was significantly increased in response to a HFD. Furthermore, the plaque numbers and size were 
unchanged in response to treatment. These data indicate that hypercaloric diet is unlikely to significantly 
affect amyloid pathology at this age. Therefore, the observed worsening of the peripheral and central 
phenotypes may be attributed to factors outside of the “amyloid cascade hypothesis” (discussed in more 
detail in the following sections). 
CORRIGENDUM: Aβ ELISA data presented in Fig. 1D of the Publication 1 depicts Aβ values on Y axis as 
picograms/mg of protein. This is incorrect and should read picograms/ml of extract. In Fig. 2C of the 
publication 2 the graphs representing soluble and insoluble levels of Aβ are identical, and it is in fact the 
same graph of insoluble Aβ (white bar- control chow; black bar – HFD). The complete and correct data is 
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presented in Table 3 of the same publication. Note that the first 6 columns of that Table depict soluble 
peptide, and the columns 7-12 the values of insoluble Aβ.  
Tau hyperphosphorylation was detected on multiple residues. In addition to S199, T205, S404 (which were 
elevated in 3-month-old APP/PS1 animals), tau S396 was also significantly upregulated in 6-month-old 
hippocampal extracts (Fig. 6 of Publication 1) of transgenic mice on a control diet. HFD treatment has 
caused increases in the phosphorylation state of tau S404 in wild-type mice along with a slight (statistically 
insignificant) increase in HFD- versus control diet-fed transgenic mice (Fig. 4 of Publication 2). The reason 
why only the data for S404 (and not any other phosphorylated taus) is presented in Publication 2, is that we 
had observed significant biological variability in S199, T205 and S396 immunoblots in response to a HFD 
treatment. As a result, we made a decision to only publish the data which was statistically sound.  
Tau-phosphorylating enzymes – control diet: On a control chow, MAPK, GSK3β and CDK5 expression 
was comparable to that observed at 3 months (see section 3.1.1 of the discussion). We did evaluate the 
expression values of additional Tau-phosphorylating kinases ERK 1/2 and JNK 1/2 in Publication 2 (Fig. 
4 of that publication). No changes were observed for these kinases in response to normal diet.   
Tau-phosphorylating kinases – HFD: MAPK levels remained unchanged, with CDK5 increase observed 
concomitantly with p35 increases in HFD-fed wild-type versus control mice (3.1.1 of the discussion). 
Phosphorylation levels of GSK3β were slightly but significantly increased in hypercaloric wild-type group. 
The results for ERK 1/2 and JNK 1/2 are much more interesting. These kinases were very significantly 
upregulated in HFD-fed mice of both groups (wild-type and APP/PS1). These data alone may already be 
sufficient to explain observed increases in tau S404 hyperphosphorylation in HFD-fed wild-type mice. But 
then, why didn’t we observe a significant increase in tau phosphorylation on the same epitope in transgenic 
mice? A possible explanation is that in this particular case, both JNK and ERK may serve a totally different 
biological role as is expected on the basis of their relationship to tau. In fact, JNK and ERK are key players 
in insulin-signaling regulation (see sections 4.2 and 4.3 of Publication 2).  
3.2.2 Mitochondrial metabolism and biogenesis 
OXPHOS: All 5 of the OXPHOS complexes were significantly downregulated in chow-fed APP/PS1 mice 
compared to wild-type controls (Fig. 7 of the Publication 2). Even though we reported no changes in 
complexes IV and V in 6-month-old animals in Publication 1 (Fig. 5), these are the results of independent 
immunoblotting experiments. In case of Publication 1, representative images of Complex V actually appear 
to show downregulation of this Complex in transgenic mice. However, when normalized to GAPDH, these 
differences disappeared. These variations in the reported data are a result of experimental variability.  
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Diet-induced obesity resulted in the significant reduction of all 5 of the OXPHOS proteins in the 
hippocampi of wild-type mice. In transgenic animals, hypercaloric diet did not further reduce the expression 
of the complexes. These data indicate that mitochondrial metabolism disruptions are severe enough in 
transgenic brains in the basal state, to the point that the presence of metabolic syndrome does not 
significantly worsen oxidative phosphorylation. 
Related molecules: In contrast to the data obtained in the hippocampi of 3-month-old animals, we have only 
observed a slight reduction in PGC-1α, but not in NRF1 and NRF2 in 6-month-old chow-fed transgenic 
mice. In addition, it appears that these molecules are downregulated in wild-type in response to normal 
ageing (compare the results between 3 and 6 month old mice in Fig. 4 of Publication 1). Furthermore, 
because PGC-1α, NRF1 and NRF2 were reduced in 3-month-old transgenic group, it seems likely that 
APP/PS1 status accelerates normal age-related physiological decline of these factors. By the age of 6 
months, a physiological steady-state is reached and therefore no further declines are observed in comparison 
to the control group. HFD treatment did induce slight, but significant reduction of PGC-1α both in the wild-
type and transgenic brains. NRF1 and NRF2 were further downregulated in APP/PS1 group only.  
Taken together, our data clearly demonstrate that metabolic syndrome significantly affects hippocampal 
mitochondrial homeostasis and biogenesis in wild-type mice. In a transgenic group, deficiencies in this 
signaling pathway are already present even before the additional insult of the hypercaloric diet. Because of 
that, HFD treatment has only a minimally worsening effect on these pathways in APP/PS1 mice. 
3.2.3 Hippocampal insulin signaling  
Control diet: Our data suggest that hippocampal insulin signaling is impaired in APP/PS1 mice. We did not 
detect changes in the hippocampal expression of INS-R itself, suggesting that the receptor is fully functional 
at this age. However, we did detect significant differences in the molecules downstream of the insulin 
receptor. Most importantly, we observed an over 2-fold increase in the pIRS2 (S723), a key negative 
regulator of downstream insulin signaling. Phosphorylation at this epitope, results in the desensitization of 
downstream signaling. In line with these observations, we observed changes in the phosphorylation state 
of AKT and GSK3β, both kinases regulated by IRS (described in more detail in Section 4.1 and Fig. 8 of 
Publication 2). Thus we can conclude that downstream insulin signaling is disturbed in transgenic mice at 
the basal state at the age of 6 months. 
Diet-induced obesity: HFD treatment resulted in much more pronounced changes in hippocampal insulin 
signaling when compared to normal diet both in the wild-type and transgenic mice. Just like in response to 
chow, neither the mRNA nor the protein levels of the INS-R were majorly affected by the treatment in any 
of the groups (there was a slight, but significant reduction of INS-R in HFD- versus chow-treated transgenic 
DISCUSSION 
97 
  
mice). pIRS2 (S723) and pGSK3β (Y216) protein levels were significantly increased in treated wild-type 
mice. In transgenic animals, the expression of both molecules was already elevated in the basal state and 
hypercaloric diet did not result in additional increases. pAKT (S473) was very significantly downregulated 
in the wild-type, with further reductions occurring in HFD-fed APP/PS1 hippocampi.  Importantly, we had 
detected significant increase in the mRNA levels of INS1 in both treated groups. INS1 is one of the two 
genes which code for insulin in mice (in humans there is only one gene). As mentioned in the discussion 
section of Publication 2, diet-induced obesity may provoke disruptions in the peripherally-expressed insulin 
transport across the BBB. The fact that we could detect elevated expression of insulin transcripts in the 
hippocampus may signify 2 things: A) Not enough insulin is reaching the brain, which could result in the 
compensatory mechanisms activating endogenous insulin expression directly in the hippocampus; B) diet-
induced obesity produces hippocampal insulin resistance, which causes excess production of endogenous 
brain insulin. Put in simple terms, in the first case there is not enough available insulin, while in the second 
case there is too much. Additional studies are necessary to determine the exact mechanism behind elevated 
insulin production in the hippocampal circuits. Another very interesting finding is the behavior of IGF1 and 
its receptor IGF1-R. IGF1 expression was increased in HFD-fed wild-type mice only (and slightly reduced 
in transgenic mice), while IGF1-R expression was reduced in only the transgenic mice exposed to the 
hypercaloric diet. Lower IGF1 expression was previously correlated with cognitive decline in AD (Kimoto 
et al., 2015), so our data are in agreement with these observations. The reasons for increased expression in 
HFD-treated wild-type mice are less clear, but may involve similar compensatory mechanisms as described 
above for insulin. In case of IGF1-R, its reduced expression was demonstrated in the post-mortem analysis 
of the brains of AD patients (Freude, Schilbach, & Schubert, 2009), so it is quite possible that the reason 
why we observe its downregulation in HFD-fed APP/PS1 mice is that diet-induced obesity accelerates AD-
like pathology in these mice. In order to be sure, however, we would need to study the expression levels of 
IGF1-R in much older APP/PS1 mice (possibly at the ages of 9 or even 12 months).  
JNK1 is another kinase whose protein expression levels demonstrated over 200% increase in the 
hippocampi of both the wild-type and transgenic groups in response to hypercaloric diet. This is very 
important, as the increased expression of JNK1 in insulin-responsive peripheral tissues including fat, 
muscle and liver, was previously linked to diet-induced obesity. JNK1 is thought to be one of the 
contributors to peripheral insulin resistance. Furthermore, brain-specific deletion of JNK1 prevented diet-
induced obesity in rodent models. However, the main site of action in the brain is thought to be the 
hypothalamic-pituitary-thyroid axis which regulates food intake and energy expenditure (Sabio & Davis, 
2010). The fact that we had detected JNK1 upregulation in the hippocampus, suggests that the hippocampal 
circuits may also be involved. 
CNS PHENOTYPE 
98 
 
The big picture: Our data demonstrate a clear involvement of hippocampal insulin signaling in diet-induced 
obesity as well as in AD pathology. Very recently (it will appear in print in the December 2015 issue of 
Current Alzheimer Research) an Italian group has published research which explored the relationship 
between HFD and the peripheral and central metabolic phenotypes. Even though the researchers have used 
total brain extracts as opposed to hippocampal extracts described in our papers, the conclusions were 
strikingly similar. That is that hypercaloric diet significantly affects mitochondrial metabolism and both the 
peripheral and central insulin homeostasis (Nuzzo et al., 2015). A general overview of how exactly that 
may happen is presented in the Fig. 4. 
3.2.4 Synaptic proteins 
Similar to the data described for 3 month old animals (section 3.1.4 of the discussion), neither SYP nor 
PSD-95 expression was affected in the hippocampus. HFD treatment did not result in any additional 
changes to these proteins (data not shown). 
3.2.5 Amyloid-degrading enzymes 
We had measured hippocampal expression of IDE and neprilysin. On a normal chow, no changes were 
observed for any of the molecules. HFD administration caused significant downregulation of IDE both in 
the wild-type and transgenic brains. Because the expression of IDE is regulated by the insulin pathway 
(overactivation of IR signaling by insulin ultimately results in increased transcription of IDE, which 
presumably shuts the pathway down), and we had established that insulin signaling is defective in response 
to diet-induced obesity, these results are not surprising. In addition, we detected significant increases in 
neprilysin protein in HFD-exposed APP/PS1 mice only. One possible explanation for these data is that 
neprilysin overexpression is triggered by the Aβ itself as a compensatory mechanism in response to the 
decreased expression of IDE. In such scenario, amyloid clearance is performed by both IDE and neprilysin: 
in the wild-type mice which do not express significantly elevated levels of amyloid, there will not be a 
physiological need for increased expression of another amyloid-degrading enzyme, which is clearly not the 
case in transgenic animals. In APP/PS1 mice, the physiological defense mechanisms aimed at removing 
excessive amyloid will be in the overdrive, which would explain high neprilysin levels.   
 
  
DISCUSSION 
99 
  
 
Figure 4. Insulin is an essential hormone which has multiple roles both in the periphery and in the CNS. 
Deficient insulin signaling in the brain may contribute to neurodegeneration observed in AD. However, 
peripheral insulin resistance may also be a direct result of AD-like pathology, even in cases when overt 
obesity is not present (see section 2.2 of the discussion). Once both the metabolic syndrome and AD-like 
pathology are combined, it is quite possible that disease pathogenesis is further accelerated, thus forming a 
positive feedback loop. (Solid arrows indicate established disease processes, dashed arrows represent 
possible disease processes and green arrows represent the effects of normal insulin signaling). *Reproduced 
from (Biessels & Reagan, 2015) 
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4. SUMMARY 
Research described in the preceding sections has revealed a number of hitherto unknown/insufficiently 
explored molecular mechanisms which may contribute to AD development in an APP/PS1 mouse model 
of FAD. In addition, hippocampal and peripheral phenotypes of HFD-induced memory loss were described 
in some detail. The main focus of the current thesis was to identify signaling networks which contribute to 
AD pathology in the relatively early-disease stages, presumably prior to the “point of no return”, when the 
pathology becomes irreversible. In the first part of the present work we have determined that mitochondrial 
homeostasis, insulin signaling and tau processing are all affected by AD-like status of APP/PS1 mice. We 
have also determined that at the age of 6 months, peripheral carbohydrate metabolism is significantly altered 
in transgenic animals. Chronic exposure to a HFD resulted in cognitive deficits even in the control animals. 
However, the exact mechanisms for this hippocampal-dependent memory loss were distinct. Our data 
suggest that elevated cerebral secretion of amyloid peptides is sufficient to produce similar phenotype as to 
that observed in response to diet-induced obesity. In transgenic animals predisposed to AD development, 
the introduction of hypercaloric diet significantly worsened existing phenotype both at the periphery and in 
the hippocampal networks. Overall, our results suggest that metabolic syndrome, diabetes and related 
comorbidities clearly do have a potential to significantly worsen the symptoms of AD disease. We identified 
specific molecules and the associated pathways which may play a role in disease progression. An integrated 
view of the proposed mechanistic changes which occur in the hippocampus is presented in Fig. 5 
(reproduced from Publication 2). 
  
DISCUSSION 
101 
  
 
Figure 5. A proposed mechanism whereby insulin signaling and mitochondrial dysregulation contribute to 
hippocampal phenotype in HFD-fed and AD-like mice. Increased circulating triglyceride levels in response 
to HFD treatment initially provoke cerebral insulin deficiency, which results in the downregulation of the 
canonical insulin signaling pathway in the hippocampus. At the same time, the free fatty acid-mediated 
increased metabolic stress subverts autologous IR-IRS-Ser/Thr kinase axis signaling, thus favoring 
heterologous regulation. This route, once activated, initiates a series of self-propagating events which 
ultimately lead to insulin resistance in a manner similar to that observed in response to elevated β-amyloid 
levels. As functional IR signaling in the hippocampus is, at least partially, regulating neuronal glucose 
entry, the inhibition of this pathway may result in the reduced supply of readily available energy to the 
mitochondria, affecting neuroplasticity. Mitochondrial OXPHOS metabolism deficiencies may thus be 
explained by two possible mechanisms: (a) as a direct result of reduced glucose availability, and (b) as a 
consequence of decreased mitochondrial biogenesis (PGC1) and/or disruptions to mitochondrial function 
due to hyperphosphorylated Tau protein and increased β-amyloid levels. *Reproduced from (Petrov et al., 
2015)
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CONCLUSION 
In my opinion, the work described in Publications 1 and 2 adequately answers the questions posed in the 
“objectives” section. Specifically: 
 
1. Characterization of the peripheral and central metabolic phenotypes at 3 and 6 months of age in 
APPswe/PS1dE9 versus the wild-type mice on a standard chow in order to: 
 
A) Determine if transgenic status has an effect on peripheral carbohydrate metabolism 
 
- Peripheral metabolic phenotype is unaffected in 3-month-old APP/PS1 mice. At 6 months of 
age, data indicate impaired glucose and insulin tolerance which is suggestive of peripheral 
insulin resistance 
 
B) Determine if hippocampal insulin signaling is altered in mice predisposed to Alzheimer 
disease development 
 
- At an early age, our results suggest the presence of initial indicators pointing toward impaired 
hippocampal insulin signaling in transgenic animals. In older mice, hippocampal insulin 
signaling is clearly impaired 
 
C) Identify molecular pathways which are altered in early stages of AD-like pathology, 
prior to amyloid plaque development and memory loss in hippocampal circuits 
 
- Mitochondrial homeostasis, the state of tau phosphorylation and amyloidogenesis are all 
affected in 3-month-old APP/PS1 mice. Furthermore, by the time the cognitive deficits do 
appear (at 6 months), the phenotype is exacerbated 
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2. Characterization of the peripheral and central metabolic phenotypes in 6-month-old 
APPswe/PS1dE9 versus the wild-type mice on a high-fat diet. In addition to the 1A and 1B 
described above, the following objectives are considered: 
 
A) Determine if high-fat diet treatment differentially affects wild-type and transgenic mice 
 
- On the peripheral level, transgenic status significantly worsens the present pathology. HFD-
fed APP/PS1 animals present with a nearly diabetic phenotype. Significant differences are also 
observed at the hippocampal level, discussed in detail in the “discussion” section 
 
B) Determine if chronic hypercaloric diet administration affects memory 
 
- The results of a 2-object Novel Object Recognition test show that HFD-fed wild type mice 
demonstrate memory loss. The same could be said about transgenic animals both on the control 
and the hypercaloric diets 
 
C) Determine if high-fat diet accelerates AD-like pathology 
 
- Our data, described in detail in the “discussion”  section, suggest that this is indeed the case 
 
D) Determine if hypercaloric diet affects hippocampal signaling molecules traditionally 
associated with AD 
 
- Insoluble levels of Aβ (1-42) were elevated in cortical extracts of HFD-fed transgenic mice. 
Some of the kinases known to promote tau phosphorylation were upregulated in response to 
diet-induced obesity. Hippocampal levels of pTau (S404) were increased in response to a HFD.
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Publication 1 
 
CURRENT RESEARCH THERAPEUTIC STRATEGIES FOR ALZHEIMER'S 
DISEASE TREATMENT 
Jaume Folch, Dmitry Petrov, Miren Ettcheto, Sonia Abad, Elena Sánchez-López, M. Luisa García, Jordi 
Olloquequi, Carlos Beas-Zarate, Carme Auladell, Antoni Camins 
Neural Plasticity (Accepted) 
 
Summary 
This Review paper describes past and possible future pharmacotherapies aimed at Alzheimer disease 
treatment. The reason for inclusion of this manuscript to this doctoral thesis presentation is that large 
portions of the Sections 3.3-3.8 of the Introduction are derived from that article. 
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Publication 2 
 
EVALUATION OF HYPOXIA INDUCIBLE FACTOR EXPRESSION IN 
INFLAMMATORY AND NEURODEGENERATIVE BRAIN MODELS 
Maria Luisa de Lemos, Aurelio Vazquez de la Torre, Dimitry Petrov, Susana Brox, Jaume Folch, Mercè 
Pallàs, Alberto Lazarowski, Carlos Beas-Zarate, Carme Auladell, Antoni Camins 
The International Journal of Biochemistry and Cell Biology (2013), 45: 1377-1388  
 
Summary 
This paper is included because the data presented here indicate that the inflammatory aspect of AD 
pathology is not yet manifested in 3-month-old APP/PS1 mouse brain. At the age of 6 months, first signs 
of cerebral inflammation are evident. This research had helped us to make an informed decision as to the 
time points which are likely relevant to the investigations described in the current thesis. As mentioned in 
the Discussion sections of the thesis presentation, we wanted to focus at an age when AD phenotype is still 
in the prodromal stages and to compare hippocampal and peripheral phenotypes in mice in which classical 
disease symptoms are already present, but presumably have not yet taken an irreversible aspect.
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Publication 3 
 
ADIPOKINE PATHWAYS ARE ALTERED IN HIPPOCAMPUS OF AN 
EXPERIMENTAL MOUSE MODEL OF ALZHEIMER’S DISEASE 
 
Pedrós I, Petrov D, Artiach G, Abad S, Ramon-Duaso C, Sureda F, Pallàs M, Beas-Zarate C, Folch J, 
Camins A 
The Journal of Nutrition, Health and Aging (2015), 19 (4): 403-412  
 
Summary 
This paper can be considered as a parallel study to the research described in the current thesis. Rather than 
focusing on the insulin signaling, we have addressed the issue of hippocampal adipokine receptor and 
cholesterol regulation. 3- and 6-month old APP/PS1 and wild-type animals on a control chow were chosen. 
Just like in the results pertaining to insulin signaling presented in the current thesis, we have detected 
significant perturbations in adipokine and cholesterol pathways at an early age, prior to amyloid plaque and 
cognitive symptoms development.   
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